

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: Interaction effect with disease severity. A retrospective study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022896
Article Type:	Research
Date Submitted by the Author:	12-Mar-2018
Complete List of Authors:	Shen, Yanfei; Intensive Care Unit Huang, Xinmei; Jinhua TCM hospital, Department of otolaryngological Zhang, Weimin; Department of Intensive Care Unit, Dongyang People's Hospital
Keywords:	sepsis, PLR, mortality, MIMIC III

SCHOLARONE™
Manuscripts

Peer Review Only

Title page

Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis:
Interaction effect with disease severity. A retrospective study.

Author names: Yanfei Shen^{1*}, Xinmei Huang^{2#}, Weimin Zhang¹.

Affiliations:

1. Department of Intensive Care Unit, Dongyang People's Hospital, No. 60, Wuning
West Road, Dongyang, Zhejiang, 322100, P.R. China.

2. Department of otolaryngological, Jinhua TCM hospital, No. 439, Shuangxi West
Road, Jinhua, Zhejiang, 322100, P.R. China.

Author Xinmei Huang contributed equally to this study and was listed as co-first
author.

* **Corresponding author:** Yanfei Shen.

E-mail: snow.shen@hotmail.com

Phone: +86-137-3890-3218

Word count: 3316.

Abstract

Objective: The role of platelet-to-lymphocyte ratio (PLR) as an indicator of inflammation has been receiving research attention. We aimed to investigate the predictive value of PLR for sepsis.

Design: A retrospective cohort study.

Setting and Participants: Data were extracted from the Multi-parameter Intelligent Monitoring in Intensive Care III database. Data on 5,537 sepsis patients were analyzed.

Methods: Logistic regression was used to explore the association between PLR and hospital mortality. Subgroup analyses were performed based on vasopressor use, acute kidney injury (AKI), and a Sequential Organ Failure Assessment (SOFA) score > 10.

Results: In the logistic model with linear spline function, a PLR > 200 was significantly (odds ratio [OR], 1.0002; 95% confidence interval [CI], 1.0001 – 1.0004) associated with mortality; the association was insignificant for PLRs \leq 200 (OR, 0.997; 95% CI, 1.19 – 1.67). In the logistic model using the PLR as a design variable, only high PLRs were significantly associated with mortality (OR, 1.29; 95% CI, 1.09 – 1.53); the association with low PLRs was insignificant (OR, 1.15; 95% CI, 0.96 – 1.38). In the subgroups with vasopressor use, AKI and a SOFA score > 10, the association between high PLR and mortality was insignificant; this remained significant in the subgroups without vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) and AKI (OR, 1.54; 95% CI, 1.20 – 1.99), and with a SOFA score \leq 10 (OR, 1.51; 95% CI, 1.17 – 1.94).

1
2
3
4 **Conclusions:** High PLRs at admission were associated with an increased risk of
5
6 mortality. In patients with vasopressor use, AKI or a SOFA score > 10, this association
7
8 was insignificant.
9

10
11 **Keywords:** sepsis, PLR, mortality, MIMIC III.
12
13

14
15 **Strengths and limitations of this study:**
16

17 The large sample size facilitated a robust conclusion.
18

19 Subgroup analysis was performed to investigate the interaction between disease
20 severity and PLR.
21

22 High PLRs was associated with an increased risk of mortality in sepsis patients
23 without vasopressor use, AKI or a SOFA score > 10.
24

25 In sepsis patients with severe condition (vasopressor use, AKI or a SOFA score > 10),
26 the association between PLRs and mortality was insignificant.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Sepsis is a major cause of morbidity and mortality, worldwide, and it results from a dysregulation of the systemic inflammatory response to infection^{1,2}. Despite significant advances in the pathophysiology and therapeutic strategies for sepsis, the mortality remains high³, at 300 deaths per 100,000 people⁴. An extremely complex systemic expression of inflammatory and anti-inflammatory response plays a critical role in the pathophysiological process of sepsis, which is strongly associated with an increased risk of mortality⁵. Identifying patients who are at a high risk of poor outcomes, in the early stage of sepsis, is vital for timely and adequate intervention⁶. While a significant amount of effort has been put into investigating promising biomarkers, the challenge of identifying these at-risk patients remains⁷.

In recent years, studies have reported that platelets and lymphocytes play critical roles in the inflammatory process. Therefore, the platelet-to-lymphocyte ratio (PLR)--a novel inflammatory factor--has received research attention in recent times, as it may act as an indicator of inflammation⁸ in a wide spectrum of diseases, such as myocardial infarction⁹, acute kidney injury (AKI)¹⁰, hepatocellular carcinoma¹¹, and non-small cell lung cancer¹².

Based on the findings of previous studies, it is reasonable to speculate the presence of a potential relationship between PLR and mortality for sepsis. However, no investigation has been conducted.

MATERIALS AND METHODS

Database introduction

All the data in the current study were extracted from an online international database--“Multi-parameter Intelligent Monitoring in Intensive Care III (MIMIC III)”—that was published by the Massachusetts Institute of Technology, with approval from the review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. All the patients in the database were de-identified for privacy protection. This database included more than 58,000 patients who were admitted to the intensive care unit (ICU) of the Beth Israel Deaconess Medical Center from 2001 to 2008. Author Y Shen obtained access to this database (certification number: 1564657), and was responsible for data extraction.

Inclusion and exclusion criteria

Adult patients meeting the criteria for sepsis were initially screened. The definition of sepsis was adapted from the recommendation in the Surviving Sepsis Campaign 2016¹³. Accordingly, sepsis was defined as the presence of a Sequential Organ Failure Assessment (SOFA) score ≥ 2 within 24 hours after ICU admission, accompanied by at least one infection site. The following criteria were used to exclude patients from this analysis: 1. Age lower than 18 years; 2. Having spent less than 48 hours in the ICU; and 3. Absence of data on the serum platelet and lymphocyte counts within 24 hours after ICU admission. For patients who were admitted to the ICU more than once, only the first ICU stay was considered in this study.

Data extraction

1
2
3 Data on the demographic characteristics, laboratory outcomes, infection sites,
4 vasopressor use, and disease severity score were extracted from the database. Only
5
6 patients with data on the serum platelet and lymphocyte counts within the first 24
7
8 hours after ICU admission were included. The first blood sample after ICU admission
9
10 was used to calculate the PLR, which was defined as the ratio of the absolute platelet
11
12 count and absolute lymphocyte count. Septic shock was considered as a special
13
14 subgroup of sepsis. However, it was difficult to identify patients with septic shock in
15
16 this database due to a lack of relevant information. Thus, data on vasopressor use
17
18 were extracted for the subgroup analysis. Vasopressor use was defined as the use of
19
20 any vasopressor agent, including norepinephrine, epinephrine, dobutamine,
21
22 dopamine or vasopressin, within 48 hours after ICU admission.
23
24
25
26
27
28
29

30 Outcome definition

31
32
33 The primary endpoint was hospital mortality, which was defined as death
34
35 during hospitalization. The presence of AKI was defined according to the
36
37 Creatinine-based Kidney Disease Improving Global Outcome criteria without urine
38
39 output^{14 15}. A 1.5-fold increase in the serum creatinine (SCr) level during the ICU stay,
40
41 relative to the level at the baseline, was considered as the presence of AKI. In the
42
43 present cohort, data on the baseline SCr values were missing in 20.3% of the cases.
44
45 For patients without previous SCr data, the estimated baseline SCr was calculated
46
47 using the following formula¹⁶: $SCr = 0.74 - 0.2 \text{ (if female)} + 0.08 \text{ (if black)} + 0.0039 * \text{age (in years)}$.
48
49
50
51
52
53

54 Management of missing data

1
2
3
4 Variables with missing data are common in the MIMIC III database, as it
5
6 comprises more than 58,000 admissions. Variables with more than 20% of missing
7
8 values were excluded from our analysis; these included serum albumin and lactate.
9
10 For variables with less than 5% of missing values, such as age and fluid balance, we
11
12 replaced the missing values with the mean values, instead of using the multiple
13
14 imputation technique. For dichotomous variables with less than 5% of missing values,
15
16 the missing values were not filled.
17
18

19 20 21 Statistical analysis

22
23 Continuous variables were expressed as mean \pm standard deviation or median
24
25 (interquartile range), as appropriate. A Student's t test, analysis of variance, Wilcoxon
26
27 rank-sum test, or Kruskal–Wallis test was used, as appropriate. Categorical data were
28
29 expressed as proportions, and compared using the χ^2 test. A knot of PLR (at a level
30
31 of around 200) was detected using the Lowess smoother technique; thus, the linear
32
33 spline function was initially used in the multivariate logistic regression. Thereafter, all
34
35 the patients were further divided into three levels: those with a PLR \leq 150 (level 1),
36
37 150 < PLR \leq 250 (level 2), and PLR > 250 (level 3). Variables including demographic
38
39 characteristics, infection sites, disease severity score, and laboratory measures
40
41 potentially associated with mortality, or those that had a p value < 0.20 in the
42
43 univariate analyses were included in the multivariate logistic regression analyses. An
44
45 extended model approach was used for covariate adjustment: Model 1 = adjusted for
46
47 age, admitted ICU type. Model 2 = Model 1+ (fluid balance at 48 hours after ICU
48
49 admission). Model 3 = Model 2 + (infection sites). Model 4 = Model 3 + (Maximum
50
51
52
53
54
55
56
57
58
59
60

1
2
3 SOFA score during the ICU stay). As we detected a U-shaped association between PLR
4
5 and mortality, we did not introduce interaction items (such as PLR multiply other
6
7 variables) in the logistic models. Instead, subgroup analyses were performed,
8
9 according to the presence of AKI and vasopressor use and the median SOFA score.
10
11 Multi-collinearity was tested using the variance inflation factor (VIF) method, with a
12
13 VIF ≥ 5 indicating the presence of multi-collinearity. All the logistic regression models
14
15 underwent a goodness of fit test. A two-tailed test was performed, and $p < 0.05$ was
16
17 considered statistically significant. All statistical analyses were performed using STATA
18
19 11.2 (College Station, TX, USA).
20
21
22
23
24
25
26
27

28 RESULTS

29 Baseline characteristics

30
31
32 Data on a total of 5,537 sepsis patients were included in this analysis. The overall
33
34 mortality observed was 25.1%. Data on the comparisons of the baseline
35
36 characteristics between the three PLR levels are listed in Table 1. The mean age at
37
38 admission was 64.9 years, and 44.9% of the participants were male. The rate of
39
40 vasopressor use (701/1780 vs. 482/1380, $p=0.01$), and a maximum SOFA score (10
41
42 (7–14) vs. 9 (7 – 12), $p<0.001$) were significantly higher in PLR level 1 than level 2; the
43
44 presence of these variables was insignificant in level 3. The mortality was significantly
45
46 higher both in those in level 1 (475/1780 vs. 291/1380, $p<0.001$) and level 3
47
48 (621/2377 vs. 291/1380, $p=0.001$).
49
50
51
52
53

54 Association between PLR and hospital mortality

1
2
3
4 The PLR was initially used as a continuous variable in the logistic model, using
5
6 linear spline function, as shown in Table 2. We observed that, for PLRs ≤ 200 , the
7
8 odds ratio (OR) of mortality was insignificant (OR, 0.997; 95% confidence interval [CI],
9
10 1.19 – 1.67), while the OR for PLRs > 200 was significant (OR, 1.0002; 95% CI, 1.0001
11
12 – 1.0004), after adjustment for covariates including the SOFA score. In the extended
13
14 multiple logistic regression analysis (Table 3), both low and the high PLR levels were
15
16 significantly associated with increased hospital mortality, in model 1 (OR, 1.41; 95%
17
18 CI, 1.19 – 1.67 and OR, 1.28; 95% CI, 1.09 – 1.51, respectively), model 2 (OR, 1.34; 95%
19
20 CI, 1.13 – 1.59 and OR, 1.23; 95% CI, 1.05 – 1.45, respectively) and model 3 (OR, 1.35;
21
22 95% CI, 1.14 – 1.61 and OR, 1.21; 95% CI, 1.03 – 1.43, respectively). However, after
23
24 adjustment for the maximum SOFA score in model 4, the OR for low PLR levels
25
26 became insignificant (OR, 1.15; 95% CI, 0.96 – 1.38, $p=0.123$), while that for high PLR
27
28 levels remained significant (OR, 1.29; 95% CI, 1.09 – 1.53, $p=0.003$). The ORs of the
29
30 covariates in model 4 are listed in Table S1.

31 32 33 34 35 36 37 38 Subgroup analysis

39
40 As the association between PLR and mortality was largely confounded by the
41
42 SOFA score (Table 3), we suspected that there was an interaction effect between
43
44 disease severity and PLR level. Thus, we performed a subgroup analysis according to
45
46 the existence of vasopressor use and AKI, and the median SOFA score (> 10 points),
47
48 as shown in Figure 1. Unlike previous findings, the association between high PLRs
49
50 and mortality became insignificant in the subgroups with vasopressor use (OR, 1.20;
51
52 95% CI, 0.95 – 1.53), AKI (OR, 1.07; 95% CI, 0.85 – 1.36), and a SOFA score > 10 (OR,
53
54
55
56
57
58
59
60

1
2
3 1.14; 95% CI, 0.90 – 1.44), and remained significant in the subgroups without
4
5 vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) and AKI (OR, 1.54; 95% CI, 1.20 –
6
7 1.99), and with a SOFA score ≤ 10 (OR, 1.51; 95% CI, 1.17 – 1.94). In the case of lower
8
9 PLRs, the OR of mortality was insignificant in all the subgroups, after adjustment,
10
11 except for the subgroup with AKI. Data on the comparisons of the characteristics
12
13 between these subgroups are listed in Table S2.
14
15
16
17
18
19
20

21 **DISCUSSION**

22
23 In this study, we observed a crude U-shaped association between the PLR and
24
25 hospital mortality in patients with sepsis. However, after adjustment for the disease
26
27 severity score, only high PLRs remained significantly associated with increased
28
29 mortality; the association with low PLRs became insignificant. Furthermore, in the
30
31 subgroup analysis, a significant association between high PLRs and mortality only
32
33 existed in the subgroups without vasopressor use and AKI, or those with a SOFA
34
35 score ≤ 10 .
36
37
38
39

40 Growing evidence indicates that immune dysregulation (especially cellular
41
42 immunity), including pro-inflammatory or anti-inflammatory responses during
43
44 different stages, is common in cases of sepsis¹⁷. In recent times, studies have
45
46 reported that platelets play an important role in both the immunomodulatory and
47
48 inflammatory process^{18,19}, by inducing the release of inflammatory cytokines²⁰ and
49
50 interacting with different kinds of bacterias and immune cells, including neutrophils,
51
52 T-lymphocytes, NK-cells and macrophages, which contribute to the initiation or
53
54
55
56
57
58
59
60

1
2
3 exacerbation of the inflammatory process ²¹. Low lymphocyte counts, which to a
4
5 certain degree represent a suppressed immune and inflammatory response ^{22 23},
6
7
8 have also been reported to be associated with inflammatory diseases, such as
9
10 cardiovascular disease ²⁴ and type II diabetes ²⁵.
11
12

13 Based on these findings, the PLR was suggested as being a novel systematic
14
15 inflammatory indicator ²⁶, and its use was initially reported in the prognostic
16
17 prediction of neoplastic disorders, such as hepatocellular carcinoma and breast
18
19 cancer. Accumulating evidence suggests that elevated PLRs are strongly associated
20
21 with increased systemic inflammation, which may contribute to the progression and
22
23 prognoses of many disorders, such as atherosclerosis ²⁷ and diabetes mellitus ²⁸.
24
25
26
27

28 In contrast to our findings, Zheng et al. ¹⁰ reported that both high and low PLRs
29
30 are associated with increased mortality, among critically ill patients with AKI, after
31
32 adjustment for the disease severity score in the Cox proportional hazards models. In
33
34 that study, unlike in ours, a significant association was also observed in patients with
35
36 vasopressin use. Several factors may contribute to this inconsistency between the
37
38 findings, such as the use of different cohorts, PLR knots, and definitions of
39
40 vasopressor use. It is worth noting that, as the association between PLRs and
41
42 outcomes varies greatly between different cohorts, the inter-heterogeneity within
43
44 critically ill patients may also lead to a biased conclusion.
45
46
47
48
49

50 Akbas et al. indicated that a high PLR was positively associated with increased
51
52 epicardial adipose tissue deposition in diabetes patients ²⁹; this may be caused by
53
54 higher inflammation rates. Wang et al. ³⁰ reviewed 134 patients with lung
55
56
57
58
59
60

1
2
3
4 adenosquamous cancer, and reported that high PLRs (> 150) were independently
5
6 associated with shorter disease-free days and lower overall survival rates. Another
7
8 study ³¹, including 270 patients with hepatocellular carcinoma, found that elevated
9
10 PLRs (above 220) were predictors of poor prognoses, while low PLRs (< 248.0) were
11
12 associated with a low tumor, node and metastasis stage, and low surgery incidence,
13
14 in 695 patients with lung cancer ³². Despite the fact that the study cohorts used in
15
16 those studies were quite different from those used in ours, the reported PLR knots
17
18 were quite similar to ours. However, the small sample sizes in those studies limited
19
20 the statistical power for further stratification and subgroup analysis of low PLR. In the
21
22 current study, we noticed that high PLRs (> 250) were associated with increased
23
24 hospital mortality. As higher platelet levels, to a certain extent, are predictive of
25
26 inflammation of a higher severity and low lymphocyte counts may represent a
27
28 suppressed immune and inflammatory response ^{22 23}, an increase in the PLR may
29
30 reflect the degree of the inflammatory and immune response to the infection, which
31
32 related to a poor prognosis.
33
34
35
36
37
38
39

40 We also detected an insignificant association between low PLRs and mortality, in
41
42 the case of sepsis. The association between low PLRs and outcomes was also
43
44 reported in several studies. In a retrospective study ³³ including 899 cases of
45
46 laryngeal cancer, patients were divided into three PLR categories (low (≤ 119.55),
47
48 moderate (> 119.55 and ≤ 193.55), and high (> 193.55)), and only patients with high
49
50 PLRs experienced poor outcomes, including malnutrition and more advanced cancer
51
52 stage; the association between outcomes and PLR levels were insignificant for those
53
54
55
56
57
58
59
60

1
2
3 with low PLRs. Despite the cohort of that study being different from ours, the
4
5 conclusion was consistent with that of our study. In the case of sepsis, a low platelet
6
7 count is potentially associated with poor outcomes. In a large study including 931
8
9 patients with sepsis, Claushuis et al. reported that patients with a low platelet count
10
11 at ICU admission had a higher disease severity score and increased mortality risk ³⁴.
12
13 Furthermore, thrombocytopenia--one of the most common hemostatic disorders in
14
15 the case of sepsis--which is related with platelet consumption, was also associated
16
17 with higher mortality ³⁵. However, in the present study, a significant association
18
19 between low PLR and mortality was not detected. Further studies are needed to
20
21 validate this conclusion.
22
23
24
25
26

27
28 Furthermore, according to the subgroup analysis, the association between high
29
30 PLR and mortality became insignificant in the subgroups with vasopressor use, AKI or
31
32 a SOFA score > 10; this association remained significant in the other subgroups. This
33
34 finding further supported our speculation that there may be an interaction between
35
36 PLR and disease severity. To the best of our knowledge, ours is the first study to
37
38 report this interaction. However, the underlying mechanism of this interaction
39
40 remains largely unknown. A critical characteristic of sepsis is fluid resuscitation, and,
41
42 in the current study, patients with vasopressor use, AKI or a SOFA score > 10, to a
43
44 certain degree, represented patients with inflammation of a higher severity, and they
45
46 may have a stronger need for fluid resuscitation. We also noticed that the fluid
47
48 balance within 48 hours after ICU admission was significantly larger in these
49
50 subgroups. It needs to be further investigated if fluid resuscitation affects the
51
52
53
54
55
56
57
58
59
60

1
2
3
4 predictive value of the PLR.
5

6 One of the strengths of our study is the large sample size, which enabled us to
7
8 adjust for confounding factors and perform subgroup analyses. However, there are
9
10 also several limitations to our study. First, the MIMIC III database comprises data on
11
12 patients from 2001; since then, the guidelines for sepsis have changed significantly.
13
14 The most recent definition of Sepsis 3.0 was used in the current study, and this may
15
16 have introduced selection bias despite the fact that most of the basic interventions
17
18 (use of fluids, vasopressors and antimicrobial agents) remained the same.
19
20 Furthermore, as a decrease in the platelet count was a part of the SOFA score, using
21
22 the definition of sepsis 3.0, to a certain degree, may lead to a relatively low mean
23
24 platelet count and potential multi-collinearity. This bias cannot be fully avoided.
25
26 However, the potential multi-collinearity was verified in all the logistic models.
27
28 Second, septic shock is a special subgroup of sepsis. However, patients with septic
29
30 shock could not be distinguished in this study. Thus, patients were divided into
31
32 subgroups, according to the existence of vasopressor use, AKI or a SOFA score >10,
33
34 which, to a certain extent, indicates the presence of an inflammatory response of a
35
36 higher severity. Third, one of the main hypotheses of our study was the interaction
37
38 effect between disease severity and PLR; yet, this interaction term was not
39
40 introduced in the logistic model due to the U-shaped association between PLR and
41
42 mortality. Further prospective studies are needed to verify our hypothesis. Finally, as
43
44 high PLRs are associated with poor outcomes in various disorders while low PLRs are
45
46 not, it is not clear if interventions aimed at changing the PLR value may improve
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 outcomes.

5
6 **Conclusion**

7
8 In patients with sepsis, a high PLR was significantly associated with poor survival,
9
10 while the association was insignificant for those with a low PLR. However, the former
11
12 association became insignificant in patients with more severe conditions, including
13
14 those with vasopressor use, AKI or a SOFA score > 10. Future studies are needed to
15
16 verify our hypothesis.
17
18

19
20 **Financial support and sponsorship:** This research received no specific grant from any
21
22 funding agency in the public, commercial or not-for-profit sectors.
23

24 **Acknowledgments:** None.

25
26 **Conflicts of interest:** None.

27
28 **Authors' contributions:**

29 Yanfei Shen.: Responsible for data extraction and writing of the manuscript.

30 Xinmei Huang.: Responsible for data analysis.

31 Weimin Zhang.: Responsible for data validation.
32
33

34
35 **Data sharing statement:** Full data set available from the corresponding author at
36
37 snow.shen@hotmail.com. However, reanalysis of the full data need to be approved by
38
39 MIMIC III Institute.
40
41
42

43
44 **REFERENCES**

- 45 1. Vincent JL. Emerging therapies for the treatment of sepsis. *Current opinion in anaesthesiology*
46 2015;28(4):411-6.
47 2. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for
48 future research. *The Lancet. Infectious diseases* 2015;15(5):581-614.
49 3. Angus DC, van der Poll T. Severe sepsis and septic shock. *The New England journal of medicine*
50 2013;369(9):840-51.
51 4. Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, et al. Goal-directed resuscitation
52 for patients with early septic shock. *The New England journal of medicine*
53 2014;371(16):1496-506.
54 5. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. *Critical care (London, England)* 2010;14(1):R15.
55
56
57
58
59
60

- 1
- 2
- 3 6. Vincent JL, Pereira AJ, Gleeson J, Backer D. Early management of sepsis. *Clinical and experimental*
- 4 *emergency medicine* 2014;1(1):3-7.
- 5 7. Hwang YJ, Chung SP, Park YS, Chung HS, Lee HS, Park JW, et al. Newly designed delta neutrophil
- 6 index-to-serum albumin ratio prognosis of early mortality in severe sepsis. *The American*
- 7 *journal of emergency medicine* 2015;33(11):1577-82.
- 8 8. Kutlucan L, Kutlucan A, Basaran B, Dagli M, Basturk A, Kozanhan B, et al. The predictive effect of
- 9 initial complete blood count of intensive care unit patients on mortality, length of
- 10 hospitalization, and nosocomial infections. *European review for medical and pharmacological*
- 11 *sciences* 2016;20(8):1467-73.
- 12 9. Hudzik B, Szkodzinski J, Korzonek-Szlacheta I, Wilczek K, Gierlotka M, Lekston A, et al.
- 13 Platelet-to-lymphocyte ratio predicts contrast-induced acute kidney injury in diabetic patients
- 14 with ST-elevation myocardial infarction. *Biomarkers in medicine* 2017;11(10):847-56.
- 15 10. Zheng CF, Liu WY, Zeng FF, Zheng MH, Shi HY, Zhou Y, et al. Prognostic value of
- 16 platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. *Critical*
- 17 *care (London, England)* 2017;21(1):238.
- 18 11. Zheng J, Cai J, Li H, Zeng K, He L, Fu H, et al. Neutrophil to Lymphocyte Ratio and Platelet to
- 19 Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with
- 20 Various Treatments: a Meta-Analysis and Systematic Review. *Cellular physiology and*
- 21 *biochemistry : international journal of experimental cellular physiology, biochemistry, and*
- 22 *pharmacology* 2017;44(3):967-81.
- 23 12. Toda M, Tsukioka T, Izumi N, Komatsu H, Okada S, Hara K, et al. Platelet-to-lymphocyte ratio
- 24 predicts the prognosis of patients with non-small cell lung cancer treated with surgery and
- 25 postoperative adjuvant chemotherapy. *Thoracic cancer* 2017.
- 26 13. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third
- 27 International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama*
- 28 2016;315(8):801-10.
- 29 14. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO
- 30 summary (Part 1). *Critical care (London, England)* 2013;17(1):204.
- 31 15. Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney
- 32 injury: a KDIGO summary (Part 2). *Critical care (London, England)* 2013;17(1):205.
- 33 16. Zavada J, Hoste E, Cartin-Ceba R, Calzavacca P, Gajic O, Clermont G, et al. A comparison of three
- 34 methods to estimate baseline creatinine for RIFLE classification. *Nephrology, dialysis,*
- 35 *transplantation : official publication of the European Dialysis and Transplant Association -*
- 36 *European Renal Association* 2010;25(12):3911-8.
- 37 17. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in
- 38 patients who die of sepsis and multiple organ failure. *Jama* 2011;306(23):2594-605.
- 39 18. Cho SY, Jeon YL, Kim W, Kim WS, Lee HJ, Lee WI, et al. Mean platelet volume and mean platelet
- 40 volume/platelet count ratio in infective endocarditis. *Platelets* 2014;25(8):559-61.
- 41 19. Azab B, Shah N, Akerman M, McGinn JT, Jr. Value of platelet/lymphocyte ratio as a predictor of
- 42 all-cause mortality after non-ST-elevation myocardial infarction. *Journal of thrombosis and*
- 43 *thrombolysis* 2012;34(3):326-34.
- 44 20. Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. *Frontiers in*
- 45 *immunology* 2015;6:98.
- 46 21. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, et al. An increase in mean platelet volume from
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- baseline is associated with mortality in patients with severe sepsis or septic shock. *PLoS one* 2015;10(3):e0119437.
22. Manzoli TF, Delgado AF, Troster EJ, de Carvalho WB, Antunes AC, Marques DM, et al. Lymphocyte count as a sign of immunoparalysis and its correlation with nutritional status in pediatric intensive care patients with sepsis: A pilot study. *Clinics (Sao Paulo)* 2016;71(11):644-49.
 23. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. *J Immunol* 2005;174(6):3765-72.
 24. Nunez J, Minana G, Bodi V, Nunez E, Sanchis J, Husser O, et al. Low lymphocyte count and cardiovascular diseases. *Current medicinal chemistry* 2011;18(21):3226-33.
 25. Otton R, Soriano FG, Verlengia R, Curi R. Diabetes induces apoptosis in lymphocytes. *The Journal of endocrinology* 2004;182(1):145-56.
 26. Akboga MK, Canpolat U, Yayla C, Ozcan F, Ozeke O, Topaloglu S, et al. Association of Platelet to Lymphocyte Ratio With Inflammation and Severity of Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease. *Angiology* 2016;67(1):89-95.
 27. Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. *PLoS one* 2013;8(7):e67688.
 28. Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. *Diabetes & metabolic syndrome* 2017;11 Suppl 1:S127-S31.
 29. Akbas EM, Hamur H, Demirtas L, Bakirci EM, Ozcicek A, Ozcicek F, et al. Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus. *Diabetology & metabolic syndrome* 2014;6:55.
 30. Wang YQ, Zhi QJ, Wang XY, Yue DS, Li K, Jiang RC. Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenocarcinoma. *Oncology letters* 2017;14(4):4331-38.
 31. Wang Y, Attar BM, Fuentes HE, Jaiswal P, Tafur AJ. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. *Journal of gastrointestinal oncology* 2017;8(6):1065-71.
 32. Wang L, Liang D, Xu X, Jin J, Li S, Tian G, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. *Oncology letters* 2017;14(6):6449-56.
 33. Mao Y, Fu Y, Gao Y, Yang A, Zhang Q. Platelet-to-lymphocyte ratio predicts long-term survival in laryngeal cancer. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery* 2017.
 34. Claushuis TA, van Vught LA, Scicluna BP, Wiewel MA, Klein Klouwenberg PM, Hoogendijk AJ, et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. *Blood* 2016;127(24):3062-72.
 35. Semeraro F, Colucci M, Caironi P, Masson S, Ammollo CT, Teli R, et al. Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis. *Critical care medicine* 2017.

Table 1 Comparison of baseline characteristics within three PLR levels

Variable	PLR ≤ 150 (n = 1780)	150 < PLR ≤ 250 (n = 1380)	PLR > 250 (n = 2377)	p
Age (years)	63.0 ± 16.6	65.0 ± 16.6	66.1 ± 15.5	< 0.001
Gender (male) [n (%)]	805 (45.2)	590 (42.7)	1096 (46.1)	0.133
BMI (Kg/m ²)	30.8 ± 8.9	34.1 ± 13.5	35.2 ± 39.5	0.001
Ethnicity				
White [n (%)]	1202 (67.5)	987 (71.5)	1761 (74.0)	0.754
Black [n (%)]	180 (10.1)	101 (7.3)	146 (6.1)	< 0.001
Asian [n (%)]	39 (2.2)	30 (2.1)	71 (2.9)	0.169
Emergency [n (%)]	1641 (92.1)	1284 (93.0)	2229 (93.7)	0.138
ICU type				
MICU [n (%)]	953 (53.5)	727 (52.6)	1362 (57.2)	0.008
CCU/CSRU [n (%)]	413 (23.2)	323 (23.4)	453 (19.0)	0.001
TSICU/SICU [n (%)]	414 (23.2)	330 (23.9)	562 (23.6)	0.908
Vasopressors				
Norepinephrine [n (%)]	566 (31.7)	374 (27.1)	711 (29.9)	0.016
Dopamine [n (%)]	198 (11.1)	151 (10.9)	256 (10.7)	0.013
Epinephrine [n (%)]	67 (3.7)	28 (2.0)	37 (1.5)	< 0.001
Vasopressin [n (%)]	156 (8.7)	88 (6.3)	172 (7.2)	0.033
Overall vasopressor use	701 (39.3)	482 (34.9)	858 (36.1)	0.022
Fluid input/output				
Fluid intake (ml/kg/48hr)	99.9 ± 60.9	90.7 ± 57.6	97.2 ± 61.2	< 0.001
Urine output (ml/kg/48hr)	42.0 ± 32.0	42.9 ± 30.3	41.9 ± 29.5	0.5659
Fluid balance (ml/kg/48hr)	46.7 ± 59.4	38.3 ± 55.1	46.0 ± 60.4	< 0.001
Infection site				
Respiratory infection	1048 (58.8)	929 (67.3)	1580 (66.4)	< 0.001
Blood infection	768 (43.1)	509 (36.8)	998 (41.9)	0.001
Urinary infection	549 (30.8)	409 (29.6)	682 (28.6)	0.323
Abdominal infection	245 (13.7)	159 (11.5)	334 (14.0)	0.072
Cerebral infection	153 (8.5)	106 (7.6)	169 (7.1)	0.206
Disease severity scores				
SOFA on ICU admission median (IQR)	6 (4–9)	5 (4–8)	5 (3–7)	< 0.001
Maximum SOFA during ICU stay median (IQR)	10 (7–14)	9 (7–12)	9 (7–12)	< 0.001
Laboratory outcomes				
Maximum serum creatinine (mg/L)	2.5 ± 2.7	2.2 ± 2.1	2.1 ± 1.9	< 0.001
Minimum hemoglobin level (g/dl)	8.3 ± 1.7	8.69 ± 1.7	8.4 ± 1.6	< 0.001
Maximum serum sodium (mmol/L)	145.1 ± 5.4	145.0 ± 5.2	144.6 ± 5.1	0.009
Maximum serum lactate (mmol/L)	4.1 ± 3.8 (n=1536)	3.4 ± 3.1 (n=1174)	3.1 ± 3.0 (n=2112)	< 0.001
Platelet count (10 ⁹ /L)	146.7 ± 88.0	225.1 ± 107.2	297.5 ± 163.4	< 0.001
Lymphocyte count (10 ⁹ /L)	2.1 ± 5.7	1.1 ± 0.5	0.68 ± 0.4	< 0.001

PLR	91.8 ± 37.1	195.8 ± 28.6	557.5 ± 484.8	< 0.001
Clinical outcomes				
ICU LOS	9.9 ± 10.1	9.3 ± 8.7	10.1 ± 9.9	0.071
Hospital LOS	17.7 ± 15.1	16.6 ± 13.5	17.2 ± 13.7	0.082
AKI [n (%)]	861 (48.3)	601 (43.5)	1080 (45.4)	0.022
Hospital mortality [n (%)]	475 (26.6)	291 (21.0)	621 (26.1)	< 0.001

Abbreviations:

PLR: platelet to lymphocyte ratio; BMI body mass index; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit; TSICU, traumatic surgical intensive care unit; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment; SAPS II, Simplified Acute Physiology Score II; IQR, interquartile range; LOS length of stay; AKI, acute kidney injury.

For peer review only

Table 2 multivariable logistic regressions of PLR using linear spline function

Variables	Crude Odds ratio	95% CI	p	Adjusted Odds ratio	95% CI	p
PLR (≤ 200)	0.997	0.996 – 0.998	< 0.001	0.9993	0.9980 – 1.0006	0.319
PLR (> 200)	1.0002	1.0001 – 1.0004	0.001	1.0002	1.0000 – 1.0003	0.025
Age (> 65)	1.77	1.56 – 2.11	< 0.001	2.32	1.99 – 2.64	< 0.001
Maximum SOFA	1.20	1.18 – 1.22	< 0.001	1.18	1.16 – 1.20	< 0.001
Urinary infection	0.66	0.57 – 0.76	< 0.001	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.29	1.13 – 1.47	< 0.001	1.25	1.09 – 1.45	0.002
Blood infection	2.14	1.89 – 2.42	< 0.001	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.006	1.005 – 1.007	< 0.001	1.002	1.0008 – 1.0031	0.001
MICU	1.34	1.15 – 1.56	< 0.001	1.15	0.97 – 1.37	0.089
CCU/CSRU	1.22	1.01 – 1.47	0.032	1.03	0.84 – 1.26	0.752

Note: The mean variance inflation factor was 2.89 and p value of goodness of fit was 0.632.

Abbreviation: PLR platelet to lymphocyte ratio; CI confidence interval; SOFA sequential organ failure assessment; MICU multiple intensive care unit; CCU coronary care unit; CSRU cardiac surgery care unit.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3 Association between three PLR levels and hospital mortality

	PLR ≤ 150		150 < PLR ≤ 250		PLR > 250	
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Model 1	1.41 (1.19 – 1.67)	< 0.001	Ref.	–	1.28 (1.09 – 1.51)	0.002
Model 2	1.34 (1.13 – 1.59)	0.001	Ref.	–	1.23 (1.05 – 1.45)	0.009
Model 3	1.35 (1.14 – 1.61)	0.001	Ref.	–	1.21 (1.03 – 1.43)	0.018
Model 4	1.15 (0.96 – 1.38)	0.123	Ref.	–	1.29 (1.09 – 1.53)	0.003

Adjusted covariates: Model 1 = age, admitted ICU type. Model 2 = Model 1+ (fluid balance at 48 hours after ICU admission). Model 3= Model 2 + (infection sites). Model 4 = Model 3+ (Maximum SOFA score during ICU stay).

Abbreviations: PLR platelet to lymphocyte ratio; OR = odds ratio; CI= confidence interval; Ref reference category.

1
2
3
4
5
6
7
8
9
10 **Figure legend:**

11
12 Figure 1: The crude and adjusted odds ratios in the subgroup analysis. PLR level 2 was used as the reference level in all the logistic models.

13
14 Abbreviations: PLR, platelet-to-lymphocyte ratio; AKI, acute kidney injury; SOFA, Sequential Organ Failure Assessment; CI, confidence interval
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47




Figure 1: The crude and adjusted odds ratios in the subgroup analysis. PLR level 2 was used as the reference level in all the logistic models.

182x102mm (300 x 300 DPI)

Table S1 Adjusted odds ratio of hospital mortality using PLR as design variable in multivariable logistic regression

Variables	Odds ratio	95% CI	p
PLR Level 1 (≤ 150)	1.15	0.96 – 1.38	0.123
PLR Level 2 (151 ~ 250)	Ref.	–	–
PLR Level 3 (> 250)	1.29	1.09 – 1.53	0.003
Age (> 65)	2.27	1.97 – 2.62	< 0.001
Maximum SOFA	1.19	1.16 – 1.21	< 0.001
Urinary infection	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.25	1.08 – 1.44	0.002
Blood infection	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.002	1.0008 – 1.0031	0.001
MICU	1.16	0.98 – 1.37	0.082
CCU/CSRU	1.04	0.84 – 1.27	0.700

Note: The mean variance inflation factor (VIF) was 2.53 and p value of goodness of fit was 0.665.


Abbreviation: PLR platelet to lymphocyte ratio; CI confidence interval; SOFA sequential organ failure assessment; MICU multiple intensive care unit; CCU coronary care unit; CSRU cardiac surgery care unit.

Table S2 Comparisons of subgroups according to the existence of vasopressor use, AKI and SOFA score

Variables	Vasopressor-use (n = 2554)	Non-Vasopressor-use (n = 2983)	p	AKI (n = 2542)	Non-AKI (n = 2995)	p	SOFA > 10 (n = 2390)	SOFA ≤ 10 (n = 2147)	p
age	66.3 ± 15.2	63.6 ± 16.8	< 0.001	65.1 ± 15.4	64.6 ± 16.8	0.211	64.0 ± 15.7	65.5 ± 16.4	< 0.001
Vasopressor-use [n (%)]	-	-	-	1321	1233	< 0.001	1554	1000	< 0.001
Fluid intake (ml/kg/48hr)	114.4 ± 661.	81.1 ± 50.0	< 0.001	94.3 ± 62.0	98.3 ± 58.8	0.013	110.7 ± 65.5	85.6 ± 53.6	< 0.001
Fluid balance (ml/kg/48hr)	63.2 ± 64.1	28.1 ± 48.5	< 0.001	48.4 ± 60.9	40.8 ± 56.9	< 0.001	62.0 ± 64.1	30.8 ± 50.6	< 0.001
Maximum SOFA median (IQR)	12 (9 – 14)	8 (6 – 11)	< 0.001	11 (8 – 14)	9 (7 – 11)	< 0.001	13 (12 – 15)	7 (6 – 9)	< 0.001
Platelet count (10 ⁹ /L)	225.0 ± 240.1	236.0 ± 148.7	0.005	219.2 ± 143.4	240.9 ± 145.5	< 0.001	208.4 ± 147.1	248.1 ± 140.8	< 0.001
Lymphocyte count (10 ⁹ /L)	1.26 ± 3.32	1.28 ± 3.32	0.890	1.21 ± 2.21	1.32 ± 4.03	0.246	1.24 ± 3.42	1.29 ± 3.24	0.529
Hospital LOS	17.8 ± 14.3	16.7 ± 14.1	0.002	19.7 ± 15.6	15.1 ± 12.3	< 0.001	19.6 ± 14.6	15.5 ± 13.4	< 0.001
AKI [n (%)]	1321	1221	< 0.001	-	-	-	1360	1182	< 0.001
Hospital mortality [n (%)]	777	612	< 0.001	875	514	< 0.001	884	505	< 0.001

Abbreviation: SOFA sequential organ failure assessment; IQR interquartile range; LOS length of stay; AKI acute kidney injury.

Figure S1 Crude relationship between hospital mortality and PLR



view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7-8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	N/A.
		(e) Describe any sensitivity analyses	N/A.
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	N/A.
		(c) Consider use of a flow diagram	N/A.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) Summarise follow-up time (eg, average and total amount)	N/A.
Outcome data	15*	Report numbers of outcome events or summary measures over time	9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

A retrospective study of platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: interaction effect with disease severity

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022896.R1
Article Type:	Research
Date Submitted by the Author:	11-May-2018
Complete List of Authors:	Shen, Yanfei; Intensive Care Unit Huang, Xinmei; Jinhua TCM hospital, Department of otolaryngological Zhang, Weimin; Department of Intensive Care Unit, Dongyang People's Hospital
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Intensive care, Infectious diseases
Keywords:	sepsis, PLR, mortality, MIMIC III

SCHOLARONE™
Manuscripts

1
2
3 **A retrospective study of platelet-to-lymphocyte ratio as a prognostic predictor**
4
5
6 **of mortality for sepsis: interaction effect with disease severity**
7
8
9

10 **Author names:** Yanfei Shen^{1*}, Xinmei Huang^{2#}, Weimin Zhang¹
11
12

13
14
15 **Affiliations:**
16

17
18 ¹ Department of Intensive Care Unit, Dongyang People's Hospital, No. 60, Wuning
19
20 West Road, Dongyang, Zhejiang, 322100, P.R. China
21

22
23 ² Department of Otolaryngology, Jinhua TCM hospital, No. 439, Shuangxi West
24
25 Road, Jinhua, Zhejiang, 322100, P.R. China
26
27

28
29
30 # Author Xinmei Huang contributed equally to this study and is listed as co-first
31
32 author
33
34

35
36
37
38 * **Corresponding author:** Yanfei Shen
39

40 E-mail: snow.shen@hotmail.com
41

42 Phone: +86-137-3890-3218
43
44

45
46
47 Word count: 2955
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: The role of platelet-to-lymphocyte ratio (PLR) as an indicator of inflammation has received recent scientific attention. We aimed to investigate the prognostic value of PLR for sepsis.

Design: Retrospective cohort study.

Setting and Participants: Data were extracted from the Medical Information Mart for Intensive Care III database. Data of 5,537 patients with sepsis were analyzed.

Methods: Logistic regression was used to explore the association between PLR and hospital mortality. Subgroup analyses were performed based on vasopressor use, acute kidney injury (AKI), and a Sequential Organ Failure Assessment (SOFA) score > 10.

Results: In the logistic model with linear spline function, a PLR > 200 was significantly associated with mortality (odds ratio [OR], 1.0002; 95% confidence interval [CI], 1.0001 – 1.0003); the association was non-significant for PLRs ≤ 200 (OR, 0.999; 95% CI, 0.998 – 1.001). In the logistic model using the PLR as a design variable, only high PLRs were significantly associated with mortality (OR, 1.29; 95% CI, 1.09 – 1.53). The association between mortality and low PLRs was non-significant (OR, 1.15; 95% CI, 0.96 – 1.38). In the subgroups with vasopressor use, AKI, and a SOFA score > 10, the association between high PLR and mortality was non-significant; this remained significant in the subgroups without vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) or AKI (OR, 1.54; 95% CI, 1.20 – 1.99), and with a SOFA score ≤ 10 (OR, 1.51; 95% CI, 1.17 – 1.94).

1
2
3 **Conclusions:** High PLRs at admission were associated with an increased risk of
4 mortality. In patients with vasopressor use, AKI, or a SOFA score > 10, this
5
6 association was non-significant.
7
8
9

10
11
12
13 **Keywords:** Sepsis, PLR, mortality, MIMIC III
14
15

16
17
18 **Strengths and limitations of this study:**

- 19
20
 - The large sample size facilitated a robust conclusion.
 - Subgroup analysis was performed to investigate the interaction between
21 disease severity and platelet-to-lymphocyte ratio.
22
 - Pre-ICU data were not available in this database, which may lead to bias.
23
 - Patients with septic shock could not be identified in this database.
24

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Sepsis is a major cause of morbidity and mortality worldwide, and it results from a dysregulation of the systemic inflammatory response to infection.^{1,2} Despite significant advances in the pathophysiology and therapeutic strategies for sepsis, the mortality remains high,³ at 300 deaths per 100,000 people.⁴ An extremely complex systemic expression of inflammatory and anti-inflammatory response plays a critical role in the pathophysiological process of sepsis, which is strongly associated with an increased risk of mortality.⁵ Identifying patients in the early stage of sepsis who are at a high risk of poor outcomes is vital for timely and adequate intervention.⁶ While a significant amount of effort has been put into investigating promising biomarkers, the challenge of identifying these at-risk patients remains.⁷

In recent years, studies have reported that platelets and lymphocytes play critical roles in the inflammatory process. Therefore, the platelet-to-lymphocyte ratio (PLR)—a novel inflammatory factor—has received recent research attention, as it may act as an indicator of inflammation⁸ in a wide spectrum of diseases, such as myocardial infarction,⁹ acute kidney injury (AKI),¹⁰ hepatocellular carcinoma,¹¹ and non-small cell lung cancer.¹²

Based on the findings of previous studies, it is reasonable to speculate the presence of a potential relationship between PLR and mortality for sepsis. However, no investigation has been conducted.

MATERIALS AND METHODS

Database introduction

All data in the current study were extracted from an online international database, “Medical Information Mart for Intensive Care III (MIMIC III),” published by the Massachusetts Institute of Technology, with approval from the review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. All patient information in the database was de-identified for privacy protection, and the need for informed consent was waived. This database included more than 58,000 patients who were admitted to the intensive care unit (ICU) of the Beth Israel Deaconess Medical Center from 2001 to 2012. The corresponding author obtained access to this database (certification number: 1564657), and was responsible for data extraction.

Inclusion and exclusion criteria

Adult patients meeting the criteria for sepsis were initially screened. The definition of sepsis was adapted from the recommendation in the Surviving Sepsis Campaign 2016.¹³ Accordingly, sepsis was defined as the presence of a Sequential Organ Failure Assessment (SOFA) score ≥ 2 within 24 hours after ICU admission, accompanied by at least one infection site. The following criteria were used to exclude patients from this analysis: 1) age lower than 18 years; 2) having spent less than 48 hours in the ICU, and 3) absence of data on the serum platelet and lymphocyte counts within 24 hours after ICU admission. For patients who were admitted to the ICU more than once, only the first ICU stay was considered in this study.

Data extraction

Data on patient demographic characteristics, laboratory outcomes, infection sites, vasopressor use, and disease severity score were extracted from the database. Only patients with data on the serum platelet and lymphocyte counts within the first 24 hours after ICU admission were included. The first blood sample after ICU admission was used to calculate the PLR, which was defined as the ratio of the absolute platelet count and absolute lymphocyte count. Septic shock was considered as a special subgroup of sepsis. However, it was difficult to identify patients with septic shock in this database due to a lack of relevant information. Thus, data on vasopressor use were extracted for the subgroup analysis. Vasopressor use was defined as the use of any vasopressor agent, including norepinephrine, epinephrine, dobutamine, dopamine, or vasopressin, within 48 hours after ICU admission.

Outcome definition

The primary endpoint was hospital mortality, which was defined as death during hospitalization. The presence of AKI was defined according to the Creatinine-based Kidney Disease Improving Global Outcome criteria without urine output.^{14 15} A 1.5-fold increase in the serum creatinine (SCr) level during the ICU stay, relative to the level at the baseline, was considered to indicate the presence of AKI. In the present cohort, data on the baseline SCr values were missing in 20.3% of the cases. For patients without previous SCr data, the estimated baseline SCr was calculated using the following formula:¹⁶ $SCr = 0.74 - 0.2 \text{ (if female)} + 0.08 \text{ (if black)} + 0.0039 * \text{age (in years)}$.

Management of missing data

Variables with missing data are common in the MIMIC III database, as it comprises more than 58,000 admissions. Variables with more than 20% of missing values were excluded from our analysis; these included serum albumin and lactate. For non-normal distribution variables with less than 5% of missing values, such as age and fluid balance, we replaced the missing values with the mean values, and for non-normal distribution parameters, missing values were replaced by the respective median, instead of using the multiple imputation technique. For dichotomous variables with less than 5% of missing values, the missing values were not imputed.

Patient and public involvement

No patient was involved in any part of this study.

Statistical analysis

Continuous variables were expressed as mean \pm standard deviation or median (interquartile range), as appropriate. A Student's t test, analysis of variance, Wilcoxon rank-sum test, or Kruskal–Wallis test was used, as appropriate. Categorical data were expressed as proportions, and compared using the χ^2 test. A knot of PLR (at a level of around 200, Supplementary Figure S1) was detected using the LOWESS smoother technique; thus, the linear spline function was initially used in the multivariate logistic regression. Thereafter, all patients were further divided into three levels: those with a PLR \leq 150 (level 1), 150 < PLR \leq 250 (level 2), and PLR > 250 (level 3). Variables including demographic characteristics, infection sites, disease severity score, and laboratory measures potentially associated with mortality,

1
2
3 or those that had a p value < 0.20 in the univariate analyses, were included in the
4
5
6 multivariate logistic regression analyses. An extended model approach was used for
7
8 covariate adjustment: Model 1 = adjusted for age, admitted ICU type. Model 2 =
9
10 Model 1 + (fluid balance at 48 hours after ICU admission). Model 3 = Model 2 +
11
12 (infection sites). Model 4 = Model 3 + (Maximum SOFA score during the ICU stay).
13
14
15 As we detected a U-shaped association between PLR and mortality, we did not
16
17 introduce interaction items (such as PLR multiplied with other variables) in the
18
19 logistic models. Instead, subgroup analyses were performed, according to the
20
21 presence of AKI and vasopressor use and the median SOFA score. Multi-collinearity
22
23 was tested using the variance inflation factor (VIF) method, with a VIF ≥ 5 indicating
24
25 the presence of multi-collinearity. All logistic regression models underwent a
26
27 goodness of fit test. A two-tailed test was performed, and $p < 0.05$ was considered
28
29 statistically significant. All statistical analyses were performed using STATA 11.2
30
31 (StataCorp, LLC, College Station, TX, USA).
32
33
34
35
36
37
38
39

40 RESULTS

41 Baseline characteristics

42
43 Data on a total of 5,537 sepsis patients were included in this analysis. The overall
44
45 mortality observed was 25.1%. Data on the comparisons of the baseline
46
47 characteristics between the three PLR levels are listed in Table 1. The mean age at
48
49 admission was 64.9 years, and 44.9% of the participants were male. The rate of
50
51 vasopressor use (701/1780 vs. 482/1380, $p = 0.01$), and a maximum SOFA score
52
53
54
55
56
57
58
59
60

1
2
3 (10 (7–14) vs. 9 (7 – 12), $p < 0.001$) were significantly higher in PLR level 1 than in
4
5
6 level 2; the presence of these variables was non-significant in level 3. The mortality
7
8 was significantly higher both in the level 1 group (475/1780 vs. 291/1380, $p < 0.001$)
9
10 and the level 3 group (621/2377 vs. 291/1380, $p = 0.001$).
11
12

13 **Association between PLR and hospital mortality**

14
15 The PLR was initially used as a continuous variable in the logistic model, using linear
16
17 spline function, as shown in Table 2. We observed that, for PLRs ≤ 200 , the odds
18
19 ratio (OR) of mortality was non-significant (OR, 0.999; 95% confidence interval [CI],
20
21 0.998 – 1.001), while the OR for PLRs > 200 was significant after adjustment for
22
23 covariates, including the SOFA score (OR, 1.0002; 95% CI, 1.0001 – 1.0003). In the
24
25 extended multiple logistic regression analysis (Table 3), both low and high PLR
26
27 levels were significantly associated with increased hospital mortality, in model 1 (OR,
28
29 1.41; 95% CI, 1.19 – 1.67 and OR, 1.28; 95% CI, 1.09 – 1.51, respectively), model 2
30
31 (OR, 1.34; 95% CI, 1.13 – 1.59 and OR, 1.23; 95% CI, 1.05 – 1.45, respectively) and
32
33 model 3 (OR, 1.35; 95% CI, 1.14 – 1.61 and OR, 1.21; 95% CI, 1.03 – 1.43,
34
35 respectively). However, after adjustment for the maximum SOFA score in model 4,
36
37 the OR for low PLR levels became non-significant (OR, 1.15; 95% CI, 0.96 – 1.38, p
38
39 = 0.123), while the OR for high PLR levels remained significant (OR, 1.29; 95% CI,
40
41 1.09 – 1.53, $p = 0.003$). The univariate results are presented in Supplementary Table
42
43 S1 and the ORs of the covariates in model 4 are listed in Supplementary Table S2.
44
45
46
47
48
49
50
51

52 **Subgroup analysis**

53
54 As the association between PLR and mortality was largely confounded by the SOFA
55
56
57
58
59
60

1
2
3 score (Table 3), we suspected that there was an interaction effect between disease
4 severity and PLR level. Thus, we performed a subgroup analysis according to the
5
6 existence of vasopressor use and AKI, and the median SOFA score (> 10 points), as
7
8 shown in Figure 1. Unlike previous findings, the association between high PLRs and
9
10 mortality became non-significant in the subgroups with vasopressor use (OR, 1.20;
11
12 95% CI, 0.95 – 1.53), AKI (OR, 1.07; 95% CI, 0.85 – 1.36), and a SOFA score > 10
13
14 (OR, 1.14; 95% CI, 0.90 – 1.44), and remained significant in the subgroups without
15
16 vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) and AKI (OR, 1.54; 95% CI, 1.20 –
17
18 1.99), and with a SOFA score \leq 10 (OR, 1.51; 95% CI, 1.17 – 1.94). In the case of
19
20 lower PLRs, the OR of mortality was non-significant in all subgroups, after
21
22 adjustment, except for the subgroup with AKI. Data on the comparisons of the
23
24 characteristics between these subgroups are listed in Supplementary Table S3.
25
26
27
28
29
30
31
32
33
34

35 DISCUSSION

36
37 In this study, we observed a crude U-shaped association between the PLR and
38
39 hospital mortality in patients with sepsis. However, after adjustment for the disease
40
41 severity score, only high PLRs remained significantly associated with increased
42
43 mortality; the association with low PLRs became non-significant. Furthermore, in the
44
45 subgroup analysis, a significant association between high PLRs and mortality only
46
47 existed in the subgroups without vasopressor use and AKI, or those with a SOFA
48
49 score \leq 10.
50
51
52
53

54 Growing evidence indicates that immune dysregulation (especially cellular
55
56
57
58
59
60

1
2
3 immunity), including pro-inflammatory or anti-inflammatory responses during
4
5 different stages, is common in cases of sepsis.¹⁷ Recent studies have reported that
6
7 platelets play an important role in both the immunomodulatory and inflammatory
8
9 process,^{18 19} by inducing the release of inflammatory cytokines²⁰ and interacting with
10
11 different kinds of bacteria and immune cells, including neutrophils, T-lymphocytes,
12
13 NK-cells, and macrophages, which contribute to the initiation or exacerbation of the
14
15 inflammatory process.²¹ Low lymphocyte counts, which to a certain degree represent
16
17 a suppressed immune and inflammatory response,^{22 23} have also been reported to
18
19 be associated with inflammatory diseases, such as cardiovascular disease²⁴ and
20
21 type II diabetes.²⁵
22
23
24
25
26
27

28 Based on these findings, the PLR was suggested as being a novel systematic
29
30 inflammatory indicator,²⁶ and its use was initially reported in the prognostic prediction
31
32 of neoplastic disorders, such as hepatocellular carcinoma and breast cancer.
33
34 Accumulating evidence suggests that elevated PLRs are strongly associated with
35
36 increased systemic inflammation, which may contribute to the progression and
37
38 prognoses of many disorders, such as atherosclerosis²⁷ and diabetes mellitus.²⁸
39
40
41
42

43 In contrast to our findings, Zheng et al.¹⁰ reported that both high and low PLRs
44
45 are associated with increased mortality among critically ill patients with AKI, after
46
47 adjustment for the disease severity score in the Cox proportional hazards models. In
48
49 that study, unlike in ours, a significant association was also observed in patients with
50
51 vasopressin use. Several factors may contribute to this inconsistency between the
52
53 findings, such as the use of different cohorts, PLR knots, and definitions of
54
55
56
57
58
59
60

1
2
3 vasopressor use. It is worth noting that, as the association between PLRs and
4
5
6 outcomes varies greatly between different cohorts, the inter-heterogeneity within
7
8 critically ill patients may also lead to a biased conclusion.
9

10 Akbas et al. indicated that a high PLR was positively associated with increased
11
12 epicardial adipose tissue deposition in diabetes patients;²⁹ this may be caused by
13
14 higher inflammation rates. Wang et al.³⁰ reviewed 134 patients with lung
15
16 adenocarcinoma, and reported that high PLRs (> 150) were independently
17
18 associated with shorter disease-free days and lower overall survival rates. Another
19
20 study,³¹ including 270 patients with hepatocellular carcinoma, found that elevated
21
22 PLRs (> 220) were predictors of poor prognoses, while low PLRs (< 248) were
23
24 associated with a low tumor, node and metastasis stage, and low surgery incidence
25
26 in 695 patients with lung cancer.³² Despite the fact that the study cohorts used in
27
28 those studies were quite different from those used in ours, the reported PLR knots
29
30 were quite similar to ours. However, the small sample sizes in those studies limited
31
32 the statistical power for further stratification and subgroup analysis of low PLR. In the
33
34 current study, we noticed that high PLRs (> 250) were associated with increased
35
36 hospital mortality. As higher platelet levels, to a certain extent, are prognostic of
37
38 inflammation of a higher severity, and low lymphocyte counts may represent a
39
40 suppressed immune and inflammatory response,^{22 23} an increase in the PLR may
41
42 reflect the degree of the inflammatory and immune response to the infection, which
43
44 relates to a poor prognosis.
45
46
47
48
49
50
51
52
53

54 We also detected a non-significant association between low PLRs and mortality
55
56
57

1
2
3 from sepsis. This association between low PLRs and outcomes was also reported in
4
5
6 several studies. In a retrospective study³³ including 899 cases of laryngeal cancer,
7
8 patients were divided into three PLR categories (low (≤ 119.55), moderate (> 119.55
9
10 and ≤ 193.55), and high (> 193.55)), and only patients with high PLRs experienced
11
12 poor outcomes, including malnutrition and more advanced cancer stage; the
13
14 association between outcomes and PLR levels were non-significant for those with
15
16 low PLRs. Despite the cohort of that study being different from ours, the conclusion
17
18 was consistent with that of our study. In the case of sepsis, a low platelet count is
19
20 potentially associated with poor outcomes. In a large study including 931 patients
21
22 with sepsis, Claushuis et al. reported that patients with a low platelet count at ICU
23
24 admission had a higher disease severity score and increased mortality risk.³⁴
25
26 Furthermore, thrombocytopenia, one of the most common hemostatic disorders in
27
28 the case of sepsis and which is related with platelet consumption, was also
29
30 associated with higher mortality.³⁵ However, in the present study, a significant
31
32 association between low PLR and mortality was not detected. Further studies are
33
34 needed to validate this conclusion.
35
36
37
38
39
40
41
42

43 Furthermore, according to the subgroup analysis, the association between high
44
45 PLR and mortality became non-significant in the subgroups with vasopressor use,
46
47 AKI, or a SOFA score > 10 ; this association remained significant in the other
48
49 subgroups. This finding further supported our speculation that there may be an
50
51 interaction between PLR and disease severity. To the best of our knowledge, ours is
52
53 the first study to report this interaction. However, the underlying mechanism of this
54
55
56
57
58
59
60

1
2
3 interaction remains largely unknown. A critical characteristic of sepsis is fluid
4 resuscitation, and, in the current study, patients with vasopressor use, AKI, or a
5 SOFA score > 10, to a certain degree, represented patients with inflammation of a
6 higher severity, and thus they may have had a stronger need for fluid resuscitation.
7
8 We also noticed that the fluid balance within 48 hours after ICU admission was
9 significantly larger in these subgroups. Whether fluid resuscitation affects the
10 prognostic value of the PLR needs further investigation.
11
12
13
14
15
16
17
18
19

20 One of the strengths of our study is the large sample size, which enabled us to
21 adjust for confounding factors and perform subgroup analyses. However, there are
22 also several limitations to our study. First, the MIMIC III database comprises data on
23 patients from 2001; since then, the guidelines for sepsis have changed significantly.
24
25 The most recent definition of Sepsis 3.0 was used in the current study, and this may
26 have introduced selection bias despite the fact that most of the basic interventions
27 (use of fluids, vasopressors, and antimicrobial agents) remained the same.
28
29 Furthermore, as a decrease in the platelet count was a part of the SOFA score, using
30 the definition of sepsis 3.0 might lead to a relatively low mean platelet count and
31 potential multi-collinearity. This bias cannot be fully avoided. However, the potential
32 multi-collinearity was verified in all the logistic models. Second, the platelet count
33 can be affected by many confounders, such as types of malignities, immunological
34 factors, and types of drugs. However, due to the retrospective nature of this study,
35 these situations could not be identified in this database. Third, septic shock is a
36 special subgroup of sepsis. However, patients with septic shock could not be
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 distinguished in this study. Thus, patients were divided into subgroups, according to
4
5 the existence of vasopressor use, AKI, or a SOFA score >10, as these may indicate
6
7 the presence of a more severe inflammatory response. Fourth, one of the main
8
9 hypotheses of our study was the interaction effect between disease severity and
10
11 PLR; however, this interaction term was not introduced in the logistic model due to
12
13 the U-shaped association between PLR and mortality. Further prospective studies
14
15 are needed to verify our hypothesis. Finally, as high PLRs are associated with poor
16
17 outcomes in various disorders while low PLRs are not, it is not clear if interventions
18
19 aimed at changing the PLR value may improve outcomes.
20
21
22
23
24

25 **Conclusion**

26
27 In patients with sepsis, a high PLR was significantly associated with poor survival,
28
29 while the association was non-significant for those with a low PLR. However, the
30
31 former association became non-significant in patients with more severe conditions,
32
33 including those with vasopressor use, AKI, or a SOFA score > 10. Future studies are
34
35 needed to verify our hypothesis.
36
37
38
39
40
41

42 **Financial support and sponsorship:** This research received no specific grant from
43
44 any funding agency in the public, commercial or not-for-profit sectors.
45
46

47 **Ethical approval:** The use of this database was approved by the review boards of
48
49 the Massachusetts Institute of Technology and Beth Israel Deaconess Medical
50
51 Center. All the patient information in the database has been de-identified for privacy
52
53 protection and the need for informed consent was waived.
54
55
56
57

Acknowledgments: None.

Conflicts of interest: None.

Authors' contributions:

Yanfei Shen: Responsible for data extraction and writing of the manuscript.

Xinmei Huang: Responsible for data analysis.

Weimin Zhang: Responsible for data validation.

Data sharing statement: The full data set used in this study is available from the corresponding author at snow.shen@hotmail.com. However, reanalysis of the full data for other use requires approval by the MIMIC III Institute.

REFERENCES

1. Vincent JL. Emerging therapies for the treatment of sepsis. *Current opinion in anaesthesiology* 2015;28(4):411-6.
2. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. *The Lancet. Infectious diseases* 2015;15(5):581-614.
3. Angus DC, van der Poll T. Severe sepsis and septic shock. *The New England journal of medicine* 2013;369(9):840-51.
4. Peake SL, Delaney A, Bailey M, et al. Goal-directed resuscitation for patients with early septic shock. *The New England journal of medicine* 2014;371(16):1496-506.
5. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. *Critical care (London, England)* 2010;14(1):R15.
6. Vincent JL, Pereira AJ, Gleeson J, et al. Early management of sepsis. *Clinical and experimental emergency medicine* 2014;1(1):3-7.
7. Hwang YJ, Chung SP, Park YS, et al. Newly designed delta neutrophil index-to-serum albumin ratio prognosis of early mortality in severe sepsis. *The American journal of emergency medicine* 2015;33(11):1577-82.
8. Kutlucan L, Kutlucan A, Basaran B, et al. The predictive effect of initial complete blood count of intensive care unit patients on mortality, length of hospitalization, and nosocomial infections. *European review for medical and pharmacological sciences* 2016;20(8):1467-73.
9. Hudzik B, Szkodzinski J, Korzonek-Szlacheta I, et al. Platelet-to-lymphocyte ratio predicts contrast-induced acute kidney injury in diabetic patients with ST-elevation myocardial infarction. *Biomarkers in medicine* 2017;11(10):847-56.
10. Zheng CF, Liu WY, Zeng FF, et al. Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. *Critical care (London, England)* 2017;21(1):238.
11. Zheng J, Cai J, Li H, et al. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as

- 1
2
3 Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a
4 Meta-Analysis and Systematic Review. *Cellular physiology and biochemistry : international*
5 *journal of experimental cellular physiology, biochemistry, and pharmacology*
6 2017;44(3):967-81.
7
8 12. Toda M, Tsukioka T, Izumi N, et al. Platelet-to-lymphocyte ratio predicts the prognosis of patients
9 with non-small cell lung cancer treated with surgery and postoperative adjuvant
10 chemotherapy. *Thoracic cancer* 2017.
11
12 13. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for
13 Sepsis and Septic Shock (Sepsis-3). *Jama* 2016;315(8):801-10.
14
15 14. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO
16 summary (Part 1). *Critical care (London, England)* 2013;17(1):204.
17
18 15. Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney
19 injury: a KDIGO summary (Part 2). *Critical care (London, England)* 2013;17(1):205.
20
21 16. Zavada J, Hoste E, Cartin-Ceba R, et al. A comparison of three methods to estimate baseline
22 creatinine for RIFLE classification. *Nephrology, dialysis, transplantation : official publication*
23 *of the European Dialysis and Transplant Association - European Renal Association*
24 2010;25(12):3911-8.
25
26 17. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple
27 organ failure. *Jama* 2011;306(23):2594-605.
28
29 18. Cho SY, Jeon YL, Kim W, et al. Mean platelet volume and mean platelet volume/platelet count
30 ratio in infective endocarditis. *Platelets* 2014;25(8):559-61.
31
32 19. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause
33 mortality after non-ST-elevation myocardial infarction. *Journal of thrombosis and*
34 *thrombolysis* 2012;34(3):326-34.
35
36 20. Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. *Frontiers in*
37 *immunology* 2015;6:98.
38
39 21. Kim CH, Kim SJ, Lee MJ, et al. An increase in mean platelet volume from baseline is associated
40 with mortality in patients with severe sepsis or septic shock. *PLoS one* 2015;10(3):e0119437.
41
42 22. Manzoli TF, Delgado AF, Troster EJ, et al. Lymphocyte count as a sign of immunoparalysis and its
43 correlation with nutritional status in pediatric intensive care patients with sepsis: A pilot
44 study. *Clinics (Sao Paulo)* 2016;71(11):644-49.
45
46 23. Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and
47 hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. *J Immunol*
48 2005;174(6):3765-72.
49
50 24. Nunez J, Minana G, Bodi V, et al. Low lymphocyte count and cardiovascular diseases. *Current*
51 *medicinal chemistry* 2011;18(21):3226-33.
52
53 25. Otton R, Soriano FG, Verlengia R, et al. Diabetes induces apoptosis in lymphocytes. *The Journal of*
54 *endocrinology* 2004;182(1):145-56.
55
56 26. Akboga MK, Canpolat U, Yayla C, et al. Association of Platelet to Lymphocyte Ratio With
57 Inflammation and Severity of Coronary Atherosclerosis in Patients With Stable Coronary
58 Artery Disease. *Angiology* 2016;67(1):89-95.
59
60 27. Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb
ischemia in peripheral arterial occlusive disease patients. *PLoS one* 2013;8(7):e67688.
28. Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful

- 1
2
3 predictive markers of prediabetes and diabetes mellitus. *Diabetes & metabolic syndrome*
4 2017;11 Suppl 1:S127-S31.
- 5 29. Akbas EM, Hamur H, Demirtas L, et al. Predictors of epicardial adipose tissue in patients with
6 type 2 diabetes mellitus. *Diabetology & metabolic syndrome* 2014;6:55.
- 7
8 30. Wang YQ, Zhi QJ, Wang XY, et al. Prognostic value of combined platelet, fibrinogen, neutrophil to
9 lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenocarcinoma
10 cancer. *Oncology letters* 2017;14(4):4331-38.
- 11 31. Wang Y, Attar BM, Fuentes HE, et al. Evaluation of the prognostic value of platelet to lymphocyte
12 ratio in patients with hepatocellular carcinoma. *Journal of gastrointestinal oncology*
13 2017;8(6):1065-71.
- 14 32. Wang L, Liang D, Xu X, et al. The prognostic value of neutrophil to lymphocyte and platelet to
15 lymphocyte ratios for patients with lung cancer. *Oncology letters* 2017;14(6):6449-56.
- 16 33. Mao Y, Fu Y, Gao Y, et al. Platelet-to-lymphocyte ratio predicts long-term survival in laryngeal
17 cancer. *European archives of oto-rhino-laryngology : official journal of the European*
18 *Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German*
19 *Society for Oto-Rhino-Laryngology - Head and Neck Surgery* 2017.
- 20 34. Claushuis TA, van Vught LA, Scicluna BP, et al. Thrombocytopenia is associated with a
21 dysregulated host response in critically ill sepsis patients. *Blood* 2016;127(24):3062-72.
- 22 35. Semeraro F, Colucci M, Caironi P, et al. Platelet Drop and Fibrinolytic Shutdown in Patients With
23 Sepsis. *Critical care medicine* 2017.
- 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Comparison of baseline characteristics within three PLR levels

Variable	PLR ≤ 150 (n = 1780)	150 < PLR ≤ 250 (n = 1380)	PLR > 250 (n = 2377)	p
Age (years)	63.0 ± 16.6	65.0 ± 16.6	66.1 ± 15.5	< 0.001
Gender (male) [n (%)]	805 (45.2)	590 (42.7)	1096 (46.1)	0.133
BMI (Kg/m ²)	30.8 ± 8.9	34.1 ± 13.5	35.2 ± 39.5	0.001
Ethnicity				
White [n (%)]	1202 (67.5)	987 (71.5)	1761 (74.0)	0.754
Black [n (%)]	180 (10.1)	101 (7.3)	146 (6.1)	< 0.001
Asian [n (%)]	39 (2.2)	30 (2.1)	71 (2.9)	0.169
Emergency [n (%)]	1641 (92.1)	1284 (93.0)	2229 (93.7)	0.138
ICU type				
MICU [n (%)]	953 (53.5)	727 (52.6)	1362 (57.2)	0.008
CCU/CSRU [n (%)]	413 (23.2)	323 (23.4)	453 (19.0)	0.001
TSICU/SICU [n (%)]	414 (23.2)	330 (23.9)	562 (23.6)	0.908
Vasopressors				
Norepinephrine [n (%)]	566 (31.7)	374 (27.1)	711 (29.9)	0.016
Dopamine [n (%)]	198 (11.1)	151 (10.9)	256 (10.7)	0.013
Epinephrine [n (%)]	67 (3.7)	28 (2.0)	37 (1.5)	< 0.001
Vasopressin [n (%)]	156 (8.7)	88 (6.3)	172 (7.2)	0.033
Overall vasopressor use	701 (39.3)	482 (34.9)	858 (36.1)	0.022
Fluid input/output				
Fluid intake (ml/kg/48hr)	99.9 ± 60.9	90.7 ± 57.6	97.2 ± 61.2	< 0.001
Urine output (ml/kg/48hr)	42.0 ± 32.0	42.9 ± 30.3	41.9 ± 29.5	0.5659
Fluid balance (ml/kg/48hr)	46.7 ± 59.4	38.3 ± 55.1	46.0 ± 60.4	< 0.001
Infection site				
Respiratory infection	1048 (58.8)	929 (67.3)	1580 (66.4)	< 0.001
Blood infection	768 (43.1)	509 (36.8)	998 (41.9)	0.001
Urinary infection	549 (30.8)	409 (29.6)	682 (28.6)	0.323
Abdominal infection	245 (13.7)	159 (11.5)	334 (14.0)	0.072
Cerebral infection	153 (8.5)	106 (7.6)	169 (7.1)	0.206
Disease severity scores				
SOFA on ICU admission median (IQR)	6 (4–9)	5 (4–8)	5 (3–7)	< 0.001
Maximum SOFA during ICU stay median (IQR)	10 (7–14)	9 (7–12)	9 (7–12)	< 0.001
Laboratory outcomes				
Maximum serum creatinine (mg/L)	2.5 ± 2.7	2.2 ± 2.1	2.1 ± 1.9	< 0.001
Minimum hemoglobin level (g/dl)	8.3 ± 1.7	8.69 ± 1.7	8.4 ± 1.6	< 0.001
Maximum serum sodium (mmol/L)	145.1 ± 5.4	145.0 ± 5.2	144.6 ± 5.1	0.009
Maximum serum lactate (mmol/L)	4.1 ± 3.8 (n=1536)	3.4 ± 3.1 (n=1174)	3.1 ± 3.0 (n=2112)	< 0.001
Platelet count (10 ⁹ /L)	146.7 ± 88.0	225.1 ± 107.2	197.5 ± 163.4	< 0.001
Lymphocyte count (10 ⁹ /L)	2.1 ± 5.7	1.1 ± 0.5	0.68 ± 0.4	< 0.001

PLR	91.8 ± 37.1	195.8 ± 28.6	557.5 ± 484.8	< 0.001
Clinical outcomes				
ICU LOS	9.9 ± 10.1	9.3 ± 8.7	10.1 ± 9.9	0.071
Hospital LOS	17.7 ± 15.1	16.6 ± 13.5	17.2 ± 13.7	0.082
AKI [n (%)]	861 (48.3)	601 (43.5)	1080 (45.4)	0.022
Hospital mortality [n (%)]	475 (26.6)	291 (21.0)	621 (26.1)	< 0.001

Abbreviations:

PLR: platelet to lymphocyte ratio; BMI body mass index; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit; TSICU, traumatic surgical intensive care unit; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment; SAPS II, Simplified Acute Physiology Score II; IQR, interquartile range; LOS length of stay; AKI, acute kidney injury.

For peer review only

Table 2 multivariable logistic regressions of PLR using linear spline function

Variables	Crude Odds ratio	95% CI	p	Adjusted Odds ratio	95% CI	p
PLR (≤ 200)	0.997	0.996 – 0.998	< 0.001	0.9993	0.9980 – 1.0006	0.319
PLR (> 200)	1.0002	1.0001 – 1.0004	0.001	1.0002	1.0000 – 1.0003	0.025
Age (> 65)	1.77	1.56 – 2.11	< 0.001	2.32	1.99 – 2.64	< 0.001
Maximum SOFA	1.20	1.18 – 1.22	< 0.001	1.18	1.16 – 1.20	< 0.001
Urinary infection	0.66	0.57 – 0.76	< 0.001	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.29	1.13 – 1.47	< 0.001	1.25	1.09 – 1.45	0.002
Blood infection	2.14	1.89 – 2.42	< 0.001	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.006	1.005 – 1.007	< 0.001	1.002	1.0008 – 1.0031	0.001
MICU	1.34	1.15 – 1.56	< 0.001	1.15	0.97 – 1.37	0.089
CCU/CSRU	1.22	1.01 – 1.47	0.032	1.03	0.84 – 1.26	0.752

Note: The mean variance inflation factor was 2.89 and p value of goodness of fit was 0.632.

Abbreviation: PLR platelet to lymphocyte ratio; CI confidence interval; SOFA sequential organ failure assessment; MICU multiple intensive care unit; CCU coronary care unit; CSRU cardiac surgery care unit.

Table 3 Association between three PLR levels and hospital mortality

	PLR ≤ 150		150 < PLR ≤ 250		PLR > 250	
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Model 1	1.41 (1.19 – 1.67)	< 0.001	Ref.	–	1.28 (1.09 – 1.51)	0.002
Model 2	1.34 (1.13 – 1.59)	0.001	Ref.	–	1.23 (1.05 – 1.45)	0.009
Model 3	1.35 (1.14 – 1.61)	0.001	Ref.	–	1.21 (1.03 – 1.43)	0.018
Model 4	1.15 (0.96 – 1.38)	0.123	Ref.	–	1.29 (1.09 – 1.53)	0.003

Adjusted covariates: Model 1 = age, admitted ICU type. Model 2 = Model 1+ (fluid balance at 48 hours after ICU admission). Model 3= Model 2 + (infection sites). Model 4 = Model 3+ (Maximum SOFA score during ICU stay).

Abbreviations: PLR platelet to lymphocyte ratio; OR = odds ratio; CI= confidence interval; Ref reference category.

1
2
3
4
5
6 **Figure legend:**
7

8 Figure 1: The crude and adjusted odds ratios in the subgroup analysis. PLR level 2
9 was used as the reference level in all of the logistic models.
10

11
12
13 Abbreviations: PLR, platelet-to-lymphocyte ratio; AKI, acute kidney injury; SOFA,
14 Sequential Organ Failure Assessment; CI, confidence interval
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: The crude and adjusted odds ratios in the subgroup analysis. PLR level 2 was used as the reference level in all of the logistic models.
 Abbreviations: PLR, platelet-to-lymphocyte ratio; AKI, acute kidney injury; SOFA, Sequential Organ Failure Assessment; CI, confidence interval

182x102mm (300 x 300 DPI)

Table S1 Risk factors associated with in-hospital mortality

Variables	Odds ratio	95% CI	p
Age (> 65)	1.77	1.56 – 2.01	< 0.001
Gender (male)	0.91	0.81 – 1.03	0.173
BMI (kg/m ²)	1.00	0.99 – 1.00	0.485
TSICU/SICU	Ref.	–	–
MICU	1.34	1.15 – 1.56	< 0.001
CCU/CSRU	1.22	1.01 – 1.47	0.032
Fluid balance (ml/kg/48hrs)	1.006	1.005 – 1.007	< 0.001
Urine output (ml/kg/48hrs)	0.98	0.98 – 0.98	< 0.001
Respiratory infection	1.29	1.13 – 1.47	< 0.001
Blood infection	2.14	1.89 – 2.42	< 0.001
Urinary infection	0.66	0.57 – 0.76	< 0.001
Abdominal infection	0.93	0.77 – 1.11	0.458
Cerebral infection	0.66	0.51 – 0.85	0.002
SOFA on ICU admission	1.15	1.13 – 1.17	< 0.001
Maximum SOFA	1.20	1.18 – 1.22	< 0.001
Maximum serum creatinine (mg/L)	1.15	1.12 – 1.19	< 0.001
Minimum hemoglobin level (g/dl)	0.84	0.81 – 0.88	< 0.001
Maximum serum sodium (mmol/L)	1.02	1.01 – 1.02	< 0.001
Platelet count (10 ⁹ /L)	0.998	0.997 – 0.998	< 0.001
Lymphocyte count (10 ⁹ /L)	0.972	0.934 – 1.01	0.163

Abbreviations: BMI, body mass index; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit; TSICU, traumatic surgical intensive care unit; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment;

Table S2 Adjusted odds ratio of hospital mortality using PLR as design variable in multivariable logistic regression

Variables	Odds ratio	95% CI	p
PLR Level 1 (≤ 150)	1.15	0.96 – 1.38	0.123
PLR Level 2 (151 ~ 250)	Ref.	–	–
PLR Level 3 (> 250)	1.29	1.09 – 1.53	0.003
Age (> 65)	2.27	1.97 – 2.62	< 0.001
Maximum SOFA	1.19	1.16 – 1.21	< 0.001
Urinary infection	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.25	1.08 – 1.44	0.002
Blood infection	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.002	1.0008 – 1.0031	0.001
MICU	1.16	0.98 – 1.37	0.082
CCU/CSRU	1.04	0.84 – 1.27	0.700

Note: The mean variance inflation factor (VIF) was 2.53 and p value of goodness of fit was 0.665.


Abbreviation: PLR, platelet to lymphocyte ratio; CI, confidence interval; SOFA, sequential organ failure assessment; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit.

Table S3 Comparisons of subgroups according to the existence of vasopressor use, AKI and SOFA score

Variables	Vasopressor-use (n = 2554)	Non-Vasopressor-use (n = 2983)	p	AKI (n = 2542)	Non-AKI (n = 2995)	p	SOFA > 10 (n = 2390)	SOFA ≤ 10 (n = 2147)	p
Age	66.3 ± 15.2	63.6 ± 16.8	< 0.001	65.1 ± 15.4	64.6 ± 16.8	0.211	64.0 ± 15.7	65.5 ± 16.4	< 0.001
Vasopressor-use [n (%)]	-	-	-	1321	1233	< 0.001	1554	1000	< 0.001
Fluid intake (ml/kg/48hr)	114.4 ± 661.	81.1 ± 50.0	< 0.001	94.3 ± 62.0	98.3 ± 58.8	0.013	110.7 ± 65.5	85.6 ± 53.6	< 0.001
Fluid balance (ml/kg/48hr)	63.2 ± 64.1	28.1 ± 48.5	< 0.001	48.4 ± 60.9	40.8 ± 56.9	< 0.001	62.0 ± 64.1	30.8 ± 50.6	< 0.001
Maximum SOFA median (IQR)	12 (9 – 14)	8 (6 – 11)	< 0.001	11 (8 – 14)	9 (7 – 11)	< 0.001	13 (12 – 15)	7 (6 – 9)	< 0.001
Platelet count (10⁹/L)	225.0 ± 240.1	236.0 ± 148.7	0.005	219.2 ± 143.4	240.9 ± 145.5	< 0.001	208.4 ± 147.1	248.1 ± 140.8	< 0.001
Lymphocyte count (10⁹/L)	1.26 ± 3.32	1.28 ± 3.32	0.890	1.21 ± 2.21	1.32 ± 4.03	0.246	1.24 ± 3.42	1.29 ± 3.24	0.529
Hospital LOS	17.8 ± 14.3	16.7 ± 14.1	0.002	19.7 ± 15.6	15.1 ± 12.3	< 0.001	19.6 ± 14.6	15.5 ± 13.4	< 0.001
AKI [n (%)]	1321	1221	< 0.001	-	-	-	1360	1182	< 0.001
Hospital mortality [n (%)]	777	612	< 0.001	875	514	< 0.001	884	505	< 0.001

Abbreviation: SOFA, sequential organ failure assessment; IQR, interquartile range; LOS, length of stay; AKI, acute kidney injury.

Figure S1 Crude relationship between hospital mortality and PLR



view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	N/A.
		(e) Describe any sensitivity analyses	N/A.
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	N/A.
		(c) Consider use of a flow diagram	N/A.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) Summarise follow-up time (eg, average and total amount)	N/A.
Outcome data	15*	Report numbers of outcome events or summary measures over time	9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: Interaction effect with disease severity. A retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022896.R2
Article Type:	Research
Date Submitted by the Author:	23-Jul-2018
Complete List of Authors:	Shen, Yanfei; Zhejiang Hospital, Intensive care unit Huang, Xinmei; Jinhua TCM hospital, Department of otolaryngological Zhang, Weimin; Department of Intensive Care Unit, Dongyang People's Hospital
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Intensive care, Infectious diseases
Keywords:	sepsis, PLR, mortality, MIMIC III

SCHOLARONE™
Manuscripts

Title page

Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis:
Interaction effect with disease severity. A retrospective study

Author names: Yanfei Shen^{1*}, Xinmei Huang^{2#}, Weimin Zhang³.

Affiliations:

1. Department of Intensive Care Unit, Zhejiang Hospital, 12# Lingyin Road, Hangzhou, Zhejiang, China.

2. Department of otolaryngological, Jinhua TCM hospital, No. 439, Shuangxi West Road, Jinhua, Zhejiang, 322100, P.R. China.

3. Department of Intensive Care Unit, Dongyang People's Hospital, No. 60, Wuning West Road, Dongyang, Zhejiang, 322100, P.R. China.

Author Xinmei Huang contributed equally to this study and was listed as co-first author.

* **Corresponding author:** Yanfei Shen.

E-mail: snow.shen@hotmail.com

Phone: +86-137-3890-3218

Word count: 3542.

Abstract

Objective: The role of platelet-to-lymphocyte ratio (PLR) as an indicator of inflammation has been the focus of research recently. We aimed to investigate the prognostic value of PLR for sepsis.

Design: A retrospective cohort study.

Setting and Participants: Data were extracted from the Multi-parameter Intelligent Monitoring in Intensive Care III database. Data on 5,537 sepsis patients were analyzed.

Methods: Logistic regression was used to explore the association between PLR and hospital mortality. Subgroup analyses were performed based on vasopressor use, acute kidney injury (AKI), and a Sequential Organ Failure Assessment (SOFA) score > 10.

Results: In the logistic model with linear spline function, a PLR > 200 was significantly (odds ratio [OR], 1.0002; 95% confidence interval [CI], 1.0001 – 1.0004) associated with mortality; the association was non-significant for PLRs \leq 200 (OR, 0.997; 95% CI, 1.19 – 1.67). In the logistic model using the PLR as a design variable, only high PLRs were significantly associated with mortality (OR, 1.29; 95% CI, 1.09 – 1.53); the association with low PLRs was non-significant (OR, 1.15; 95% CI, 0.96 – 1.38). In the subgroups with vasopressor use, AKI, and a SOFA score > 10, the association between high PLR and mortality was non-significant; this remained significant in the subgroups without vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) and AKI (OR, 1.54; 95% CI, 1.20 – 1.99), and with a SOFA score \leq 10 (OR, 1.51; 95% CI, 1.17 – 1.94).

1
2
3
4 **Conclusions:** High PLRs at admission were associated with an increased risk of
5
6 mortality. In patients with vasopressor use, AKI, or a SOFA score > 10, this association
7
8 was non-significant.
9

10
11 **Keywords:** sepsis, PLR, mortality, MIMIC III.
12
13
14
15

16 **Strengths and limitations of this study:**

17 The large sample size facilitated a robust conclusion.

18
19 Subgroup analysis was performed to investigate the interaction between disease
20
21 severity and PLR.
22
23

24 Pre-ICU data were not available in this database which may lead to bias.

25
26 Patients with septic shock could not be identified in this database.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

1
2
3
4 Sepsis is a major cause of morbidity and mortality, worldwide, and it results
5
6 from a dysregulation of the systemic inflammatory response to infection ^{1 2}. Despite
7
8 significant advances in the pathophysiology and therapeutic strategies for sepsis, the
9
10 mortality remains high ³, at 300 deaths per 100,000 people ⁴. An extremely complex
11
12 systemic expression of inflammatory and anti-inflammatory response plays a critical
13
14 role in the pathophysiological process of sepsis, which is strongly associated with an
15
16 increased risk of mortality ⁵. Identifying patients who are at a high risk of poor
17
18 outcomes, in the early stage of sepsis, is vital for timely and adequate intervention ⁶.
19
20 While a significant amount of effort has been put into investigating promising
21
22 biomarkers, the challenge of identifying these at-risk patients remains ⁷.
23
24
25
26
27
28
29

30 In recent years, studies have reported that platelets and lymphocytes play critical
31
32 roles in the inflammatory process. Therefore, the platelet-to-lymphocyte ratio (PLR)--a
33
34 novel inflammatory factor--has received research attention recently, as it may act as
35
36 an indicator of inflammation ⁸ in a wide spectrum of diseases, such as myocardial
37
38 infarction ⁹, acute kidney injury (AKI) ¹⁰, hepatocellular carcinoma ¹¹, and non-small
39
40 cell lung cancer ¹².
41
42
43
44

45 Based on the findings of previous studies, it is reasonable to speculate the
46
47 presence of a potential relationship between PLR and mortality for sepsis. However,
48
49 no investigation has been conducted. Therefore, in this study we aimed to investigate
50
51 the prognostic value of PLR for sepsis.
52
53
54
55
56
57

58 **MATERIALS AND METHODS**

59
60

Database introduction

All the data in the current study were extracted from an online international database—Multi-parameter Intelligent Monitoring in Intensive Care III (MIMIC III)—that was published by the Massachusetts Institute of Technology, with approval from the review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. All the patients in the database were de-identified for privacy protection and the need for informed consent was waived. This database included more than 58,000 patients who were admitted to the intensive care unit (ICU) of the Beth Israel Deaconess Medical Center from 2001 to 2008. Author Y Shen obtained access to this database (certification number: 1564657), and was responsible for data extraction.

Inclusion and exclusion criteria

Adult patients meeting the criteria for sepsis were initially screened. The definition of sepsis was adapted from the recommendation in the Surviving Sepsis Campaign 2016¹³. Accordingly, sepsis was defined as the presence of a Sequential Organ Failure Assessment (SOFA) score ≥ 2 within 24 hours after ICU admission, accompanied by at least one infection site. The following criteria were used to exclude patients from this analysis: 1. Age lower than 18 years; 2. Having spent less than 48 hours in the ICU; and 3. Absence of data on the serum platelet and lymphocyte counts within 24 hours after ICU admission. For patients who were admitted to the ICU more than once, only the first ICU stay was considered in this study.

Data extraction

1
2
3
4 Data on the demographic characteristics, laboratory outcomes, infection sites,
5
6 vasopressor use, and disease severity score were extracted from the database. Only
7
8 patients with data on the serum platelet and lymphocyte counts within the first 24
9
10 hours after ICU admission were included. The first blood sample after ICU admission
11
12 was used to calculate the PLR, which was defined as the ratio of the absolute platelet
13
14 count and absolute lymphocyte count. Septic shock was considered as a special
15
16 subgroup of sepsis. However, it was difficult to identify patients with septic shock in
17
18 this database due to a lack of relevant information. Thus, data on vasopressor use
19
20 were extracted for the subgroup analysis. Vasopressor use was defined as the use of
21
22 any vasopressor agent, including norepinephrine, epinephrine, dobutamine,
23
24 dopamine or vasopressin, within 48 hours after ICU admission.
25
26
27
28
29
30
31

32 Outcome definition

33
34
35 The primary endpoint was hospital mortality, which was defined as death during
36
37 hospitalization. The presence of AKI was defined according to the Creatinine-based
38
39 Kidney Disease Improving Global Outcome criteria without urine output^{14 15}. A 1.5-
40
41 fold increase in the serum creatinine (SCr) level during the ICU stay, relative to the
42
43 level at the baseline, was considered as the presence of AKI. In the present cohort,
44
45 data on the baseline SCr values were missing in 20.3% of the cases. As AKI was not the
46
47 primary outcome, we used a reported estimation equation¹⁶ (reported median
48
49 absolute error was 0.1–0.2 mg/dL) to calculate the missing values for patients without
50
51 previous SCr data: $SCr = 0.74 - 0.2 \text{ (if female)} + 0.08 \text{ (if black)} + 0.0039 * \text{age (in years)}$.
52
53
54
55
56
57

58 Management of missing data

1
2
3
4 Variables with missing data are common in the MIMIC III database, as it comprises
5
6 more than 58,000 admissions. The percentage of missing values of serum lactate and
7
8 albumin was 12.9% and 26.3%, respectively. For serum lactate, the crude comparison
9
10 within three PLR levels is presented in Table 1, but was not included in the logistic
11
12 models. The serum albumin was completely excluded from this study. For the rest of
13
14 the variables included in the current study, the percentage of missing values was less
15
16 than 5%. For normal distribution variables, such as age and fluid balance, we replaced
17
18 the missing values with their mean values; For non-normal distribution parameters,
19
20 missing values were replaced by the respective median, instead of using the multiple
21
22 imputation technique. For dichotomous variables with less than 5% of missing values,
23
24 the missing values were not filled.
25
26
27
28
29
30
31

32 Patient and Public Involvement:

33
34
35 No patient was involved in any part of this study.
36

37 Statistical analysis

38
39
40 Continuous variables were expressed as mean \pm standard deviation or median
41
42 (interquartile range), as appropriate. A Student's t test, analysis of variance, Wilcoxon
43
44 rank-sum test, or Kruskal–Wallis test was used, as appropriate. Categorical data were
45
46 expressed as proportions, and compared using the χ^2 test. A knot of PLR (at a level of
47
48 around 200) was detected using the Lowess smoother technique; thus, the linear
49
50 spline function was initially used in the multivariate logistic regression. Thereafter, all
51
52 the patients were further divided into three levels: those with a PLR \leq 150 (level 1),
53
54 150 < PLR \leq 250 (level 2), and PLR > 250 (level 3). Variables including demographic
55
56
57
58
59
60

1
2
3
4 characteristics, infection sites, disease severity score, and laboratory measures
5
6 potentially associated with mortality, or those that had a p value < 0.20 in the
7
8 univariate analyses were included in the multivariate logistic regression analyses^{17 18}.
9
10 An extended model approach was used for covariate adjustment: Model 1 = adjusted
11
12 for age, admitted ICU type. Model 2 = Model 1+ (fluid balance at 48 hours after ICU
13
14 admission). Model 3 = Model 2 + (infection sites). Model 4 = Model 3 + (Maximum
15
16 SOFA score during the ICU stay). As we detected a U-shaped association between PLR
17
18 and mortality, we did not introduce interaction items (such as PLR multiply other
19
20 variables) in the logistic models. Instead, subgroup analyses were performed,
21
22 according to the presence of AKI and vasopressor use and the median SOFA score.
23
24 Multi-collinearity was tested using the variance inflation factor (VIF) method, with a
25
26 VIF ≥ 5 indicating the presence of multi-collinearity. All the logistic regression models
27
28 underwent a goodness of fit test. A two-tailed test was performed, and $p < 0.05$ was
29
30 considered statistically significant. All statistical analyses were performed using STATA
31
32 11.2 (College Station, TX, USA).
33
34
35
36
37
38
39
40
41
42
43
44

45 RESULTS

46 Baseline characteristics

47
48
49
50 Data on a total of 5,537 sepsis patients were included in this analysis. The overall
51
52 mortality observed was 25.1%. Data on the comparisons of the baseline characteristics
53
54 between the three PLR levels are listed in Table 1. The mean age at admission was
55
56 64.9 years, and 44.9% of the participants were male. The rate of vasopressor use
57
58
59
60

1
2
3
4 (701/1780 vs. 482/1380, $p=0.01$), and a maximum SOFA score (10 (7–14) vs. 9 (7–12),
5
6
7 $p<0.001$) were significantly higher in PLR level 1 than level 2; the presence of these
8
9 variables was non-significant in level 3. The mortality was significantly higher among
10
11 those in level 1 (475/1780 vs. 291/1380, $p<0.001$) and level 3 (621/2377 vs. 291/1380,
12
13
14 $p=0.001$).

17 Association between PLR and hospital mortality

19 The PLR was initially used as a continuous variable in the logistic model, using
20
21 linear spline function, as shown in Table 2. We observed that, for PLRs ≤ 200 , the odds
22
23 ratio (OR) of mortality was non-significant (OR, 0.997; 95% confidence interval [CI],
24
25 1.19 – 1.67), while the OR for PLRs > 200 was significant (OR, 1.0002; 95% CI, 1.0001 –
26
27 1.0004), after adjustment for covariates including the SOFA score, with a mean VIF of
28
29 2.89. The crude association between hospital mortality and PLR was also presented in
30
31 Figure S1. In the extended multiple logistic regression analysis (Table 3), both low and
32
33 high PLR levels were significantly associated with increased hospital mortality, in
34
35 model 1 (OR, 1.41; 95% CI, 1.19 – 1.67 and OR, 1.28; 95% CI, 1.09 – 1.51, respectively),
36
37 model 2 (OR, 1.34; 95% CI, 1.13 – 1.59 and OR, 1.23; 95% CI, 1.05 – 1.45, respectively)
38
39 and model 3 (OR, 1.35; 95% CI, 1.14 – 1.61 and OR, 1.21; 95% CI, 1.03 – 1.43,
40
41 respectively). However, after adjustment for the maximum SOFA score in model 4, the
42
43 OR for low PLR levels became non-significant (OR, 1.15; 95% CI, 0.96 – 1.38, $p=0.123$),
44
45 while that for high PLR levels remained significant (OR, 1.29; 95% CI, 1.09 – 1.53,
46
47 $p=0.003$), with a mean VIF of 2.53. The ORs of the covariates in model 4 are listed in
48
49 Table S1.
50
51
52
53
54
55
56
57
58
59
60

Subgroup analysis

As the association between PLR and mortality was largely confounded by the SOFA score (Table 3), we suspected that there was an interaction effect between disease severity and PLR level. Thus, we performed a subgroup analysis according to the existence of vasopressor use and AKI, and the median SOFA score (> 10 points), as shown in Figure 1. Unlike previous findings, the association between high PLRs and mortality became non-significant in the subgroups with vasopressor use (OR, 1.20; 95% CI, 0.95 – 1.53), AKI (OR, 1.07; 95% CI, 0.85 – 1.36), and a SOFA score > 10 (OR, 1.14; 95% CI, 0.90 – 1.44), and remained significant in the subgroups without vasopressor use (OR, 1.39; 95% CI, 1.08 – 1.77) and AKI (OR, 1.54; 95% CI, 1.20 – 1.99), and with a SOFA score \leq 10 (OR, 1.51; 95% CI, 1.17 – 1.94). In the case of lower PLRs, the OR of mortality was non-significant in all the subgroups, after adjustment, except for the subgroup with AKI. Data on the comparisons of the characteristics between these subgroups are listed in Table S2. Finally, all the potential risk factors associated with in-hospital mortality were listed in Table S3.

DISCUSSION

In this study, we observed a crude U-shaped association between the PLR and hospital mortality in patients with sepsis. However, after adjustment for the disease severity score, only high PLRs remained significantly associated with increased mortality; the association with low PLRs became non-significant. Furthermore, in the subgroup analysis, a significant association between high PLRs and mortality only

1
2
3
4 existed in the subgroups without vasopressor use and AKI, or those with a SOFA score
5
6 ≤ 10 .
7
8

9 Growing evidence indicates that immune dysregulation (especially cellular
10 immunity), including pro-inflammatory or anti-inflammatory responses during
11 different stages, is common in cases of sepsis ¹⁹. Recently, studies have reported that
12 platelets play an important role in both the immunomodulatory and inflammatory
13 process ^{20 21}, by inducing the release of inflammatory cytokines ²² and interacting with
14 different kinds of bacteria and immune cells, including neutrophils, T-lymphocytes,
15 NK-cells and macrophages, which contribute to the initiation or exacerbation of the
16 inflammatory process ²³. Low lymphocyte counts, which to a certain degree represent
17 a suppressed immune and inflammatory response ^{24 25}, have also been reported to be
18 associated with inflammatory diseases, such as cardiovascular disease ²⁶ and type II
19 diabetes ²⁷.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Based on these findings, the PLR was suggested as being a novel systematic
38 inflammatory indicator ²⁸, and its use was initially reported in the prognostic
39 prediction of neoplastic disorders, such as hepatocellular carcinoma and breast cancer.
40 Accumulating evidence suggests that elevated PLRs are strongly associated with
41 increased systemic inflammation, which may contribute to the progression and
42 prognoses of many disorders, such as atherosclerosis ²⁹ and diabetes mellitus ³⁰.
43
44
45
46
47
48
49
50
51
52

53 In contrast to our findings, Zheng et al. ¹⁰ reported that both high and low PLRs
54 are associated with increased mortality, among critically ill patients with AKI, after
55 adjustment for the disease severity score in the Cox proportional hazards models. In
56
57
58
59
60

1
2
3
4 that study, unlike in ours, a significant association was also observed in patients with
5
6 vasopressin use. Several factors may contribute to this inconsistency between the
7
8 findings, such as the use of different cohorts, PLR knots, and definitions of vasopressor
9
10 use. It is worth noting that, as the association between PLRs and outcomes varies
11
12 greatly between different cohorts, the inter-heterogeneity within critically ill patients
13
14 may also lead to a biased conclusion.
15
16
17

18
19 Akbas et al. indicated that a high PLR was positively associated with increased
20
21 epicardial adipose tissue deposition in diabetes patients ³¹; this may be caused by
22
23 higher inflammation rates. Wang et al. ³² reviewed 134 patients with lung
24
25 adenocarcinoma, and reported that high PLRs (> 150) were independently
26
27 associated with shorter disease-free days and lower overall survival rates. Another
28
29 study ³³, including 270 patients with hepatocellular carcinoma, found that elevated
30
31 PLRs (above 220) were predictors of poor prognoses, while low PLRs (< 248.0) were
32
33 associated with a lower tumor, node and metastasis stage, and low surgery incidence,
34
35 in 695 patients with lung cancer ³⁴. Despite the fact that the study cohorts used in
36
37 those studies were quite different from those used in ours, the reported PLR knots
38
39 were quite similar to ours. However, the small sample sizes in those studies limited
40
41 the statistical power for further stratification and subgroup analysis of low PLR. In the
42
43 current study, we noticed that high PLRs (> 250) were associated with increased
44
45 hospital mortality. As higher platelet levels, to a certain extent, are prognostic of
46
47 inflammation of a higher severity and low lymphocyte counts may represent a
48
49 suppressed immune and inflammatory response ^{24 25}, an increase in the PLR may
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 reflect the degree of the inflammatory and immune response to the infection, which
5
6 is related to a poor prognosis.
7

8
9 We also detected a non-significant association between low PLRs and mortality,
10
11 in the case of sepsis. The association between low PLRs and outcomes was also
12
13 reported in several studies. In a retrospective study³⁵ including 899 cases of laryngeal
14
15 cancer, patients were divided into three PLR categories (low (≤ 119.55), moderate ($>$
16
17 119.55 and ≤ 193.55), and high (> 193.55)), and only patients with high PLRs
18
19 experienced poor outcomes, including malnutrition and more advanced cancer stage;
20
21 the association between outcomes and PLR levels were non-significant for those with
22
23 low PLRs. Despite the cohort of that study being different from ours, the conclusion
24
25 was consistent with that of our study. In the case of sepsis, a low platelet count is
26
27 potentially associated with poor outcomes. In a large study including 931 patients with
28
29 sepsis, Claushuis et al. reported that patients with a low platelet count at ICU
30
31 admission had a higher disease severity score and increased mortality risk³⁶.
32
33 Furthermore, thrombocytopenia--one of the most common hemostatic disorders in
34
35 the case of sepsis--which is related with platelet consumption, was also associated
36
37 with higher mortality³⁷. However, in the present study, a significant association
38
39 between low PLR and mortality was not detected. Further studies are needed to
40
41 validate this conclusion.
42
43
44
45
46
47
48
49
50
51

52
53 Furthermore, according to the subgroup analysis, the association between high
54
55 PLR and mortality became non-significant in the subgroups with vasopressor use, AKI,
56
57 or a SOFA score > 10 ; this association remained significant in the other subgroups. This
58
59
60

1
2
3
4 finding further supported our speculation that there may be an interaction between
5
6 PLR and disease severity. To the best of our knowledge, ours is the first study to report
7
8 this interaction. However, the underlying mechanism of this interaction remains
9
10 largely unknown. A critical characteristic of sepsis is fluid resuscitation, and, in the
11
12 current study, patients with vasopressor use, AKI, or a SOFA score > 10, to a certain
13
14 degree, represented patients with inflammation of a higher severity, and they may
15
16 have a stronger need for fluid resuscitation. We also noticed that the fluid balance
17
18 within 48 hours after ICU admission was significantly larger in these subgroups. It
19
20 needs to be further investigated if fluid resuscitation affects the prognostic value of
21
22 the PLR.
23
24
25
26
27
28
29

30 One of the strengths of our study is the large sample size, which enabled us to
31
32 adjust for confounding factors and perform subgroup analyses. However, there are
33
34 also several limitations to our study. First, the MIMIC III database comprises data on
35
36 patients from 2001; since then, the guidelines for sepsis have changed significantly.
37
38 The most recent definition of Sepsis 3.0 was used in the current study, and this may
39
40 have introduced selection bias despite the fact that most of the basic interventions
41
42 (use of fluids, vasopressors, and antimicrobial agents) remained the same.
43
44 Furthermore, as a decrease in the platelet count was a part of the SOFA score, using
45
46 the definition of Sepsis 3.0, to a certain degree, may lead to a relatively low mean
47
48 platelet count and potential multi-collinearity. This bias cannot be fully avoided.
49
50 However, the potential multi-collinearity was verified in all the logistic models. Second,
51
52 the platelet count can be affected by many cofounders, such as kinds of
53
54
55
56
57
58
59
60

1
2
3
4 malignancies, immunological factors and kinds of drugs. However, due to the
5
6 nature of retrospective study, these situations cannot be identified in this database.
7
8
9 In addition, in the logistic model using PLR as a continuous variable (Table 2), the OR
10
11 was relatively small, despite the wide PLR range. Caution is therefore needed when
12
13 interpreting these findings. Third, septic shock is a special subgroup of sepsis. However,
14
15 patients with septic shock could not be distinguished in this study. Thus, patients were
16
17 divided into subgroups, according to the existence of vasopressor use, AKI, or a SOFA
18
19 score >10, which, to a certain extent, indicates the presence of an inflammatory
20
21 response of a higher severity. Fourth, one of the main hypotheses of our study was
22
23 the interaction effect between disease severity and PLR; yet, this interaction term was
24
25 not introduced in the logistic model due to the U-shaped association between PLR and
26
27 mortality. Further prospective studies are needed to verify our hypothesis. Finally, as
28
29 high PLRs are associated with poor outcomes in various disorders while low PLRs are
30
31 not, it is not clear if interventions aimed at changing the PLR value may improve
32
33 outcomes. Finally, as
34
35 high PLRs are associated with poor outcomes in various disorders while low PLRs are
36
37 not, it is not clear if interventions aimed at changing the PLR value may improve
38
39 outcomes.
40
41
42

43 **Conclusion**

44
45 In patients with sepsis, a high PLR was significantly associated with poor survival,
46
47 while the association was non-significant for those with a low PLR. However, the
48
49 former association became non-significant in patients with more severe conditions,
50
51 including those with vasopressor use, AKI, or a SOFA score > 10. Future studies are
52
53 needed to verify our hypothesis.
54
55
56

57
58 **Financial support and sponsorship:** This research received no specific grant from
59
60 any funding agency in the public, commercial or not-for-profit sectors.

Ethical approval: All the data presented in this study were extracted from an online database named “MIMIC III,” which was approved by the review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center. Thus, requirement for individual patient consent was waived because the study did not impact clinical care and all protected health information was de-identified.

Acknowledgments: None.

Conflicts of interest: None.

Authors' contributions:

Yanfei Shen.: Responsible for data extraction and writing of the manuscript.

Xinmei Huang.: Responsible for data analysis.

Weimin Zhang.: Responsible for data validation.

Data sharing statement: The full data set is available from the corresponding author at snow.shen@hotmail.com. However, reanalysis of the full data need to be approved by MIMIC III Institute.

REFERENCES

1. Vincent JL. Emerging therapies for the treatment of sepsis. *Current opinion in anaesthesiology* 2015;28(4):411-6. doi: 10.1097/ACO.0000000000000210 [published Online First: 2015/06/19]
2. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. *The Lancet Infectious diseases* 2015;15(5):581-614. doi: 10.1016/S1473-3099(15)70112-X [published Online First: 2015/05/02]
3. Angus DC, van der Poll T. Severe sepsis and septic shock. *The New England journal of medicine* 2013;369(9):840-51. doi: 10.1056/NEJMra1208623 [published Online First: 2013/08/30]
4. Peake SL, Delaney A, Bailey M, et al. Goal-directed resuscitation for patients with early septic shock. *The New England journal of medicine* 2014;371(16):1496-506. doi: 10.1056/NEJMoa1404380 [published Online First: 2014/10/02]
5. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. *Critical care (London, England)* 2010;14(1):R15. doi: 10.1186/cc8872 [published Online First: 2010/02/11]
6. Vincent JL, Pereira AJ, Gleeson J, et al. Early management of sepsis. *Clinical and experimental emergency medicine* 2014;1(1):3-7. doi: 10.15441/ceem.14.005 [published Online First: 2014/09/30]
7. Hwang YJ, Chung SP, Park YS, et al. Newly designed delta neutrophil index-to-serum albumin ratio prognosis of early mortality in severe sepsis. *The American journal of emergency medicine* 2015;33(11):1577-82. doi: 10.1016/j.ajem.2015.06.012 [published Online First: 2015/08/05]
8. Kutlucan L, Kutlucan A, Basaran B, et al. The predictive effect of initial complete blood count of

- intensive care unit patients on mortality, length of hospitalization, and nosocomial infections. *European review for medical and pharmacological sciences* 2016;20(8):1467-73. [published Online First: 2016/05/11]
9. Hudzik B, Szkodzinski J, Korzonek-Szlacheta I, et al. Platelet-to-lymphocyte ratio predicts contrast-induced acute kidney injury in diabetic patients with ST-elevation myocardial infarction. *Biomarkers in medicine* 2017;11(10):847-56. doi: 10.2217/bmm-2017-0120 [published Online First: 2017/10/05]
10. Zheng CF, Liu WY, Zeng FF, et al. Prognostic value of platelet-to-lymphocyte ratios among critically ill patients with acute kidney injury. *Critical care (London, England)* 2017;21(1):238. doi: 10.1186/s13054-017-1821-z [published Online First: 2017/09/09]
11. Zheng J, Cai J, Li H, et al. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology* 2017;44(3):967-81. doi: 10.1159/000485396 [published Online First: 2017/11/28]
12. Toda M, Tsukioka T, Izumi N, et al. Platelet-to-lymphocyte ratio predicts the prognosis of patients with non-small cell lung cancer treated with surgery and postoperative adjuvant chemotherapy. *Thoracic cancer* 2017 doi: 10.1111/1759-7714.12547 [published Online First: 2017/11/07]
13. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016;315(8):801-10. doi: 10.1001/jama.2016.0287 [published Online First: 2016/02/24]
14. Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Critical care (London, England)* 2013;17(1):204. doi: 10.1186/cc11454 [published Online First: 2013/02/12]
15. Lameire N, Kellum JA. Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2). *Critical care (London, England)* 2013;17(1):205. doi: 10.1186/cc11455 [published Online First: 2013/02/12]
16. Zavada J, Hoste E, Cartin-Ceba R, et al. A comparison of three methods to estimate baseline creatinine for RIFLE classification. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2010;25(12):3911-8. doi: 10.1093/ndt/gfp766 [published Online First: 2010/01/27]
17. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. *Am J Epidemiol* 1989;129(1):125-37.
18. Zhang Z, Lu B, Ni H, et al. Prediction of pulmonary edema by plasma protein levels in patients with sepsis. *J Crit Care* 2012;27(6):623-9. doi: 10.1016/j.jcrc.2012.08.007
19. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. *Jama* 2011;306(23):2594-605. doi: 10.1001/jama.2011.1829 [published Online First: 2011/12/22]
20. Cho SY, Jeon YL, Kim W, et al. Mean platelet volume and mean platelet volume/platelet count ratio in infective endocarditis. *Platelets* 2014;25(8):559-61. doi: 10.3109/09537104.2013.857394 [published Online First: 2013/11/12]
21. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. *Journal of thrombosis and thrombolysis*

- 2012;34(3):326-34. doi: 10.1007/s11239-012-0718-6 [published Online First: 2012/04/03]
22. Nording HM, Seizer P, Langer HF. Platelets in inflammation and atherogenesis. *Frontiers in immunology* 2015;6:98. doi: 10.3389/fimmu.2015.00098 [published Online First: 2015/03/24]
23. Kim CH, Kim SJ, Lee MJ, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. *PloS one* 2015;10(3):e0119437. doi: 10.1371/journal.pone.0119437 [published Online First: 2015/03/06]
24. Manzoli TF, Delgado AF, Troster EJ, et al. Lymphocyte count as a sign of immunoparalysis and its correlation with nutritional status in pediatric intensive care patients with sepsis: A pilot study. *Clinics (Sao Paulo)* 2016;71(11):644-49. doi: 10.6061/clinics/2016(11)05 [published Online First: 2016/12/17]
25. Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. *J Immunol* 2005;174(6):3765-72. [published Online First: 2005/03/08]
26. Nunez J, Minana G, Bodi V, et al. Low lymphocyte count and cardiovascular diseases. *Current medicinal chemistry* 2011;18(21):3226-33. [published Online First: 2011/06/16]
27. Otton R, Soriano FG, Verlengia R, et al. Diabetes induces apoptosis in lymphocytes. *The Journal of endocrinology* 2004;182(1):145-56. [published Online First: 2004/07/01]
28. Akboga MK, Canpolat U, Yayla C, et al. Association of Platelet to Lymphocyte Ratio With Inflammation and Severity of Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease. *Angiology* 2016;67(1):89-95. doi: 10.1177/0003319715583186 [published Online First: 2015/04/30]
29. Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. *PloS one* 2013;8(7):e67688. doi: 10.1371/journal.pone.0067688 [published Online First: 2013/07/12]
30. Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. *Diabetes & metabolic syndrome* 2017;11 Suppl 1:S127-S31. doi: 10.1016/j.dsx.2016.12.021 [published Online First: 2016/12/27]
31. Akbas EM, Hamur H, Demirtas L, et al. Predictors of epicardial adipose tissue in patients with type 2 diabetes mellitus. *Diabetology & metabolic syndrome* 2014;6:55. doi: 10.1186/1758-5996-6-55 [published Online First: 2014/05/14]
32. Wang YQ, Zhi QJ, Wang XY, et al. Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. *Oncology letters* 2017;14(4):4331-38. doi: 10.3892/ol.2017.6660 [published Online First: 2017/09/26]
33. Wang Y, Attar BM, Fuentes HE, et al. Evaluation of the prognostic value of platelet to lymphocyte ratio in patients with hepatocellular carcinoma. *Journal of gastrointestinal oncology* 2017;8(6):1065-71. doi: 10.21037/jgo.2017.09.06
34. Wang L, Liang D, Xu X, et al. The prognostic value of neutrophil to lymphocyte and platelet to lymphocyte ratios for patients with lung cancer. *Oncology letters* 2017;14(6):6449-56. doi: 10.3892/ol.2017.7047 [published Online First: 2017/11/23]
35. Mao Y, Fu Y, Gao Y, et al. Platelet-to-lymphocyte ratio predicts long-term survival in laryngeal cancer. *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery* 2017 doi: 10.1007/s00405-017-4849-4 [published Online

1
2
3 First: 2017/12/25]

4 36. Claushuis TA, van Vught LA, Scicluna BP, et al. Thrombocytopenia is associated with a dysregulated
5 host response in critically ill sepsis patients. *Blood* 2016;127(24):3062-72. doi: 10.1182/blood-
6 2015-11-680744 [published Online First: 2016/03/10]

7
8 37. Semeraro F, Colucci M, Caironi P, et al. Platelet Drop and Fibrinolytic Shutdown in Patients With
9 Sepsis. *Critical care medicine* 2017 doi: 10.1097/CCM.0000000000002919 [published Online
10 First: 2017/12/21]

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure legend:

Figure 1: The crude and adjusted odds ratios in the subgroup analysis. PLR level 2 was used as the reference level in all the logistic models.

Abbreviations: PLR, platelet-to-lymphocyte ratio; AKI, acute kidney injury; SOFA, Sequential Organ Failure Assessment; CI, confidence interval

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Comparison of baseline characteristics within three PLR levels

Variable	PLR ≤ 150 (n = 1780)	150 < PLR ≤ 250 (n = 1380)	PLR > 250 (n = 2377)	p
Age (years)	63.0 ± 16.6	65.0 ± 16.6	66.1 ± 15.5	< 0.001
Gender (male) [n (%)]	805 (45.2)	590 (42.7)	1096 (46.1)	0.133
BMI (Kg/m ²)	30.8 ± 8.9	34.1 ± 13.5	35.2 ± 39.5	0.001
Ethnicity				
White [n (%)]	1202 (67.5)	987 (71.5)	1761 (74.0)	0.754
Black [n (%)]	180 (10.1)	101 (7.3)	146 (6.1)	< 0.001
Asian [n (%)]	39 (2.2)	30 (2.1)	71 (2.9)	0.169
Emergency [n (%)]	1641 (92.1)	1284 (93.0)	2229 (93.7)	0.138
ICU type				
MICU [n (%)]	953 (53.5)	727 (52.6)	1362 (57.2)	0.008
CCU/CSRU [n (%)]	413 (23.2)	323 (23.4)	453 (19.0)	0.001
TSICU/SICU [n (%)]	414 (23.2)	330 (23.9)	562 (23.6)	0.908
Vasopressors				
Norepinephrine [n (%)]	566 (31.7)	374 (27.1)	711 (29.9)	0.016
Dopamine [n (%)]	198 (11.1)	151 (10.9)	256 (10.7)	0.013
Epinephrine [n (%)]	67 (3.7)	28 (2.0)	37 (1.5)	< 0.001
Vasopressin [n (%)]	156 (8.7)	88 (6.3)	172 (7.2)	0.033
Overall vasopressor use	701 (39.3)	482 (34.9)	858 (36.1)	0.022
Fluid input/output				
Fluid intake (ml/kg/48hr)	99.9 ± 60.9	90.7 ± 57.6	97.2 ± 61.2	< 0.001
Urine output (ml/kg/48hr)	42.0 ± 32.0	42.9 ± 30.3	41.9 ± 29.5	0.5659
Fluid balance (ml/kg/48hr)	46.7 ± 59.4	38.3 ± 55.1	46.0 ± 60.4	< 0.001
Infection site				
Respiratory infection	1048 (58.8)	929 (67.3)	1580 (66.4)	< 0.001
Blood infection	768 (43.1)	509 (36.8)	998 (41.9)	0.001
Urinary infection	549 (30.8)	409 (29.6)	682 (28.6)	0.323
Abdominal infection	245 (13.7)	159 (11.5)	334 (14.0)	0.072
Cerebral infection	153 (8.5)	106 (7.6)	169 (7.1)	0.206
Disease severity scores				
SOFA on ICU admission median (IQR)	6 (4–9)	5 (4–8)	5 (3–7)	< 0.001
Maximum SOFA during ICU stay median (IQR)	10 (7–14)	9 (7–12)	9 (7–12)	< 0.001
Laboratory outcomes				
Maximum serum creatinine (mg/L)	2.5 ± 2.7	2.2 ± 2.1	2.1 ± 1.9	< 0.001
Minimum hemoglobin level (g/dl)	8.3 ± 1.7	8.69 ± 1.7	8.4 ± 1.6	< 0.001
Maximum serum sodium (mmol/L)	145.1 ± 5.4	145.0 ± 5.2	144.6 ± 5.1	0.009
Maximum serum lactate (mmol/L)	4.1 ± 3.8 (n=1536)	3.4 ± 3.1 (n=1174)	3.1 ± 3.0 (n=2112)	< 0.001
Platelet count (10 ⁹ /L)	146.7 ± 88.0	225.1 ± 107.2	197.5 ± 163.4	< 0.001

Lymphocyte count (10⁹/L)	2.1 ± 5.7	1.1 ± 0.5	0.68 ± 0.4	< 0.001
PLR	91.8 ± 37.1	195.8 ± 28.6	557.5 ± 484.8	< 0.001
Clinical outcomes				
ICU LOS	9.9 ± 10.1	9.3 ± 8.7	10.1 ± 9.9	0.071
Hospital LOS	17.7 ± 15.1	16.6 ± 13.5	17.2 ± 13.7	0.082
AKI [n (%)]	861 (48.3)	601 (43.5)	1080 (45.4)	0.022
Hospital mortality [n (%)]	475 (26.6)	291 (21.0)	621 (26.1)	< 0.001

Abbreviations:

PLR: platelet to lymphocyte ratio; BMI body mass index; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit; TSICU, traumatic surgical intensive care unit; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment; SAPS II, Simplified Acute Physiology Score II; IQR, interquartile range; LOS length of stay; AKI, acute kidney injury.

For peer review only

Table 2 multivariable logistic regressions of PLR using linear spline function

Variables	Crude Odds ratio	95% CI	p	Adjusted Odds ratio	95% CI	p
PLR (≤ 200)	0.997	0.996 – 0.998	< 0.001	0.9993	0.9980 – 1.0006	0.319
PLR (> 200)	1.0002	1.0001 – 1.0004	0.001	1.0002	1.0000 – 1.0003	0.025
Age (> 65)	1.77	1.56 – 2.11	< 0.001	2.32	1.99 – 2.64	< 0.001
Maximum SOFA	1.20	1.18 – 1.22	< 0.001	1.18	1.16 – 1.20	< 0.001
Urinary infection	0.66	0.57 – 0.76	< 0.001	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.29	1.13 – 1.47	< 0.001	1.25	1.09 – 1.45	0.002
Blood infection	2.14	1.89 – 2.42	< 0.001	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.006	1.005 – 1.007	< 0.001	1.002	1.0008 – 1.0031	0.001
MICU	1.34	1.15 – 1.56	< 0.001	1.15	0.97 – 1.37	0.089
CCU/CSRU	1.22	1.01 – 1.47	0.032	1.03	0.84 – 1.26	0.752

Note: The mean variance inflation factor was 2.89 and p value of goodness of fit was 0.632.

Abbreviation: PLR platelet to lymphocyte ratio; CI confidence interval; SOFA sequential organ failure assessment; MICU multiple intensive care unit; CCU coronary care unit; CSRU cardiac surgery care unit.


Table 3 Association between three PLR levels and hospital mortality

	PLR ≤ 150		150 < PLR ≤ 250		PLR > 250	
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Model 1	1.41 (1.19 – 1.67)	< 0.001	Ref.	–	1.28 (1.09 – 1.51)	0.002
Model 2	1.34 (1.13 – 1.59)	0.001	Ref.	–	1.23 (1.05 – 1.45)	0.009
Model 3	1.35 (1.14 – 1.61)	0.001	Ref.	–	1.21 (1.03 – 1.43)	0.018
Model 4	1.15 (0.96 – 1.38)	0.123	Ref.	–	1.29 (1.09 – 1.53)	0.003

Adjusted covariates: Model 1 = age, admitted ICU type. Model 2 = Model 1+ (fluid balance at 48 hours after ICU admission). Model 3= Model 2 + (infection sites). Model 4 = Model 3+ (Maximum SOFA score during ICU stay).

The mean variance inflation factor was 2.53 and p value of goodness of fit was 0.665 for Model 4.

Abbreviations: PLR platelet to lymphocyte ratio; OR = odds ratio; CI= confidence interval; Ref reference category.



The crude and adjusted odds ratios in the subgroup analysis. PLR level 2 was used as the reference level in all the logistic models.

Abbreviations: PLR, platelet-to-lymphocyte ratio; AKI, acute kidney injury; SOFA, Sequential Organ Failure Assessment; CI, confidence interval

182x102mm (300 x 300 DPI)

Table S1 Adjusted odds ratio of hospital mortality using PLR as design variable in multivariable logistic regression

Variables	Odds ratio	95% CI	p
PLR Level 1 (≤ 150)	1.15	0.96 – 1.38	0.123
PLR Level 2 (151 ~ 250)	Ref.	–	–
PLR Level 3 (> 250)	1.29	1.09 – 1.53	0.003
Age (> 65)	2.27	1.97 – 2.62	< 0.001
Maximum SOFA	1.19	1.16 – 1.21	< 0.001
Urinary infection	0.65	0.56 – 0.76	< 0.001
Respiratory infection	1.25	1.08 – 1.44	0.002
Blood infection	1.49	1.29 – 1.71	< 0.001
Fluid balance (ml/kg/48hrs)	1.002	1.0008 – 1.0031	0.001
MICU	1.16	0.98 – 1.37	0.082
CCU/CSRU	1.04	0.84 – 1.27	0.700

Note: The mean variance inflation factor (VIF) was 2.53 and p value of goodness of fit was 0.665.

Abbreviation: PLR platelet to lymphocyte ratio; CI confidence interval; SOFA sequential organ failure assessment; MICU multiple intensive care unit; CCU coronary care unit; CSRU cardiac surgery care unit.

Table S2 Comparisons of subgroups according to the existence of vasopressor use, AKI and SOFA score

Variables	Vasopressor-use (n = 2554)	Non-Vasopressor-use (n = 2983)	p	AKI (n = 2542)	Non-AKI (n = 2995)	p	SOFA > 10 (n = 2390)	SOFA ≤ 10 (n = 2147)	p
age	66.3 ± 15.2	63.6 ± 16.8	< 0.001	65.1 ± 15.4	64.6 ± 16.8	0.211	64.0 ± 15.7	65.5 ± 16.4	< 0.001
Vasopressor-use [n (%)]	-	-	-	1321	1233	< 0.001	1554	1000	< 0.001
Fluid intake (ml/kg/48hr)	114.4 ± 661.	81.1 ± 50.0	< 0.001	94.3 ± 62.0	98.3 ± 58.8	0.013	110.7 ± 65.5	85.6 ± 53.6	< 0.001
Fluid balance (ml/kg/48hr)	63.2 ± 64.1	28.1 ± 48.5	< 0.001	48.4 ± 60.9	40.8 ± 56.9	< 0.001	62.0 ± 64.1	30.8 ± 50.6	< 0.001
Maximum SOFA median (IQR)	12 (9 – 14)	8 (6 – 11)	< 0.001	11 (8 – 14)	9 (7 – 11)	< 0.001	13 (12 – 15)	7 (6 – 9)	< 0.001
Platelet count (10 ⁹ /L)	225.0 ± 240.1	236.0 ± 148.7	0.005	219.2 ± 143.4	240.9 ± 145.5	< 0.001	208.4 ± 147.1	248.1 ± 140.8	< 0.001
Lymphocyte count (10 ⁹ /L)	1.26 ± 3.32	1.28 ± 3.32	0.890	1.21 ± 2.21	1.32 ± 4.03	0.246	1.24 ± 3.42	1.29 ± 3.24	0.529
Hospital LOS	17.8 ± 14.3	16.7 ± 14.1	0.002	19.7 ± 15.6	15.1 ± 12.3	< 0.001	19.6 ± 14.6	15.5 ± 13.4	< 0.001
AKI [n (%)]	1321	1221	< 0.001	-	-	-	1360	1182	< 0.001
Hospital mortality [n (%)]	777	612	< 0.001	875	514	< 0.001	884	505	< 0.001


Abbreviation: SOFA sequential organ failure assessment; IQR interquartile range; LOS length of stay; AKI acute kidney injury.

Table S3 Risk factors associated with in-hospital mortality

Variables	Odds ratio	95% CI	p
Age (> 65)	1.77	1.56 – 2.01	< 0.001
Gender (male)	0.91	0.81 – 1.03	0.173
BMI (Kg/m ²)	1.00	0.99 – 1.00	0.485
TSICU/SICU	Ref.	–	–
MICU	1.34	1.15 – 1.56	< 0.001
CCU/CSRU	1.22	1.01 – 1.47	0.032
Fluid balance (ml/kg/48hrs)	1.006	1.005 – 1.007	< 0.001
Urine output (ml/kg/48hrs)	0.98	0.98 – 0.98	< 0.001
Respiratory infection	1.29	1.13 – 1.47	< 0.001
Blood infection	2.14	1.89 – 2.42	< 0.001
Urinary infection	0.66	0.57 – 0.76	< 0.001
Abdominal infection	0.93	0.77 – 1.11	0.458
Cerebral infection	0.66	0.51 – 0.85	0.002
SOFA on ICU admission	1.15	1.13 – 1.17	< 0.001
Maximum SOFA	1.20	1.18 – 1.22	< 0.001
Maximum serum creatinine (mg/L)	1.15	1.12 – 1.19	< 0.001
Minimum hemoglobin level (g/dl)	0.84	0.81 – 0.88	< 0.001
Maximum serum sodium (mmol/L)	1.02	1.01 – 1.02	< 0.001
Platelet count (10 ⁹ /L)	0.998	0.997 – 0.998	< 0.001
Lymphocyte count (10 ⁹ /L)	0.972	0.934 – 1.01	0.163

Abbreviations: BMI body mass index; MICU, multiple intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery care unit; TSICU, traumatic surgical intensive care unit; SICU, surgical intensive care unit; SOFA, sequential organ failure assessment;

Figure S1 Crude relationship between hospital mortality and PLR



view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8
		(b) Describe any methods used to examine subgroups and interactions	7-8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	N/A.
		(e) Describe any sensitivity analyses	N/A.
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	N/A.
		(c) Consider use of a flow diagram	N/A.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) Summarise follow-up time (eg, average and total amount)	N/A.
Outcome data	15*	Report numbers of outcome events or summary measures over time	9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			
Key results	18	Summarise key results with reference to study objectives	10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	N/A.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	16

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.